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SUMMARY 
Perfluorocarbon nanodroplets (PFCnDs) are an emerging class of nanoagents for 
biomedical applications. These nanoparticles are unique in their ability to phase change 
from liquid nanodroplet to gas microbubble when activated by electromagnetic energy. 
The ability of PFCnDs to phase change when triggered via an energy source has been 
utilized widely in the field of ultrasound (US) imaging and therapy. Upon phase change 
from a liquid nanodroplet to a gas microbubble by an ultrasound pulse, PFCnDs can 
provide US imaging contrast and can act as delivery vehicles for various types of cargo. 
PFCnDs used in US therapy have also been employed to act as mechanical agents, creating 
pores in cell membranes and interrogating biological barriers. Recently, laser-activated 
PFCnDs have been investigated. This subset of PFCnDs are vaporized optically and require 
a highly absorbing optical trigger contained within the droplet to induce phase change. The 
dual ultrasound and photoacoustic (PA) imaging contrast inherently provided by laser-
activated PFCnDs is used in a variety of imaging techniques, from super-resolution 
imaging to molecular and functional imaging. In addition, applications of laser-activated 
PFCnDs as a therapeutic agent are currently being explored. 
Due to their versatile nature and dual imaging contrast, laser-activated PFCnDs 
present themselves as a promising biomedical imaging and therapy tool. In particular, 
laser-activated PFCnDs can be used to address certain challenges involved in treating 
diseases and disorders of the central nervous system (CNS). One major roadblock to 
successful treatment of neurological diseases is the blood brain barrier (BBB), a 
semipermeable barrier that often prevents extravasation of therapeutics or imaging contrast 
 xvii 
from the vasculature into brain tissue. To address this challenge, laser-activated PFCnDs 
can be developed as mechanical agents, to open the BBB noninvasively. Furthermore, 
laser-activated PFCnD US/PA imaging contrast can also be utilized for in vivo 
neuroimaging techniques. Therefore, the goal of this work is to develop laser-activated 
PFCnDs as a tool in neurological applications, ranging from opening biological barriers to 
providing US/PA imaging contrast within the CNS. 
Specifically, PFCnDs are synthesized to open the BBB and are evaluated 
qualitatively, histologically, and through US/PA imaging techniques. In addition, laser 
parameters used to trigger PFCnD vaporization are optimized to ensure safe and effective 
laser-activated PFCnD induced BBB opening. Laser-activated PFCnDs are also evaluated 
as a US/PA neuroimaging contrast agent through in vitro and in vivo studies. Overall, the 
results of these studies showcase the far-reaching capabilities of laser-activated PFCnDs in 
neurological applications. 
 1 
CHAPTER 1. INTRODUCTION 
1.1 Current challenges in treatment and monitoring of neurological diseases  
Diseases and disorders of the central nervous system present a unique set of 
challenges to researchers and clinicians when it comes to diagnosis, imaging, and therapy. 
One challenge of the CNS is the protective layer of bone surrounding the brain [1]. As a 
result, imaging of the CNS is limited to modalities such as MRI, PET, and fluorescence 
imaging [1-3]. Although these techniques provide insight, they still have limitations. MRI 
is costly, bulky, and requires dual imaging with a modality like PET, which uses ionizing 
radiation, to obtain both functional and anatomical information [2]. Fluorescence imaging 
is limited to depths of about 1 mm and requires an invasive optical window to enable 
visualization of the tissue, thus limiting its utility in whole brain imaging [3]. Not only does 
the skull make imaging a challenge, but it also creates difficulties during treatment. 
Localized treatments often require direct injections or incisions into the brain [4]. To 
perform these treatments, portions of the skull must be removed to reach the tissue [1, 4-
6]. As a result, these treatments are invasive and create the possibility for infection to occur 
post-surgery [5, 6]. Furthermore, if re-treatment is needed, bone may need to be removed 
again, creating further complications [6].  
In addition to the complications caused by the skull when treating diseases of the 
brain, there is also a physiological barrier that prevents successful monitoring and therapy 
of the brain. The blood brain barrier (BBB) is a physiological barrier that prevents 
noninvasive delivery of therapeutics to the brain and imaging of contrast agents in the brain 
[4-7]. This biological barrier can be described as a non-permeable barrier that limits the 
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access of molecules into the cells of the brain [4, 8]. It consists of endothelial cells 
connected by tight junctions that prevent the passage of large molecules. The function of 
the BBB is to prevent toxins and pathogens from entering the brain tissue [9]. Although 
toxin blockage is desirable, the barrier creates a challenge for therapeutic drugs intended 
to treat diseases that occur in the brain. Since only small molecule drugs with molecular 
weights under 500 Daltons (Da) can pass through the barrier in therapeutic amounts, the 
range of treatable diseases is limited [5, 9, 10]. Furthermore, the application of contrast 
agents in the CNS has also been limited due to their size [4, 10]. To address these 
challenges, there have been many approaches to opening the BBB, including 
biopharmaceutical methods and invasive procedures [5]. As aforementioned, invasive 
procedures often require the removal of bone to enable direct injections or incisions into 
the tissue, leaving the body vulnerable to infection [4]. Biopharmaceutical methods like 
mannitol enable noninvasive opening, however, their effects are not local but widespread 
[8]. As a result, there is a need for a more efficient method of noninvasive neurological 
treatment and monitoring. 
1.2 Noninvasive blood brain barrier opening using focused ultrasound 
A noninvasive method that has been recently developed to overcome these 
challenges is microbubble assisted focused ultrasound (FUS) opening of the BBB [11]. 
FUS enables transient opening of the BBB by geometrically targeting a localized area of 
the tissue for opening [9]. A focused ultrasound pulse, in conjunction with microbubbles, 
can be used to temporarily permeabilize the BBB, allowing for transport of larger 
molecules across the barrier [4, 11]. While the mechanisms of this disruption are not fully 
understood, it is hypothesized that the interaction between oscillating microbubbles and 
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the endothelial tight junctions results in stretching of tight junctions and an increase in 
uptake of larger molecules through mechanotransduction pathways [9, 12]. This method of 
focused ultrasound is often described as therapeutic ultrasound, as it is typically lower in 
frequency, higher in intensity, and composed of longer pulses in comparison to ultrasound 
for medical imaging [13, 14]. Furthermore, microbubble assisted FUS is categorized as 
non-thermal therapeutic ultrasound, which is characterized by acoustic cavitation, i.e., the 
formation, growth, and collapse of gas bubbles [13, 14].  
Microbubble assisted FUS for BBB opening is a technique that has been evaluated 
for safety and efficacy [15-18]. FUS frequency, pulse duration, pulse repetition frequency 
(PRF), and pressure amplitude, as well as microbubble composition and dose have been 
examined to determine the optimal range of parameters [10, 19-26]. Consequently, this 
technology is used in applications ranging from small animal studies to clinical trials [27, 
28].  As such, microbubble assisted FUS BBB opening has the potential to treat various 
neurological disorders such as Alzheimer’s, ALS, Huntington’s, stroke, and Parkinson’s 
[29]. 
Although FUS opening of the BBB has made great progress, the approach is limited 
in its use of microbubbles. Microbubbles are micrometer sized gas bubbles typically made 
of a perfluorocarbon gas and a lipid shell [29]. These particles are used widely as an 
ultrasonic contrast agent because the gas core of the bubble provides strong ultrasound 
contrast. However, microbubbles have short circulation times, which makes it difficult to 
use these bubbles for an extended FUS opening or imaging session [30]. Furthermore, their 
micrometer size prevents them from leaving the vasculature, which also limits their use to 
the circulatory system. Given their gas core, microbubbles cannot encapsulate any sort of 
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cargo, making them less efficient drug carriers. Overall, they are capable of opening 
biological barriers and providing intravascular contrast but otherwise do not perform any 
other tasks for the CNS. 
1.3 Ultrasound imaging and applications in the brain 
Ultrasound (US) imaging is a widely used imaging modality in clinical applications 
due to its low-cost, portability, and safe use of non-ionizing radiation [31]. US imaging of 
tissue is achieved by sending and receiving acoustic waves, with the resulting interaction 
of the waves and tissue providing an anatomical map. Ultrasound irradiates tissue with 
high-frequency sound waves, above 20 kHz. The images that are generated using 
ultrasound are dependent upon the properties of the tissue, defined by acoustic impedance 
[31]. Acoustic impedance (Z) is described by the density of the tissue (ρ, kg/m3) and the 
speed of sound of the tissue (c, m/s) as shown in (1).   
𝑍 =  𝜌 · 𝑐 (1) 
 
When ultrasound is transmitted and interacts with tissue, the portion of the 
ultrasound wave reflected back and the resulting portion that is scattered or continues to 
propagate is proportional to the difference in acoustic impedance between the two 
materials. Larger acoustic impedance mismatches result in a higher percentage of reflected 
ultrasound waves and appear brighter on grayscale images. Bone, for example, has an 
acoustic impedance of 7.75 kg/(s·m2) whereas brain tissue has an acoustic impedance of 
1.60 kg/(s·m2) [32], resulting in a large impedance mismatch between the skull and brain. 
Additionally, the attenuation coefficient, used to describe the amplitude loss of propagating 
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ultrasound waves through a medium, of bone is also high, resulting in many challenges 
when it comes to employing ultrasound as a neuroimaging modality [32]. 
 Currently, ultrasound imaging of the brain has been limited due to the acoustic 
characteristics of the skull. Common clinical neuroimaging methods rely on imaging 
situations where skull interference is reduced. For example, prenatal and pediatric imaging 
is capable of US imaging due to the open space in the fontanel prior to hardening [33-37]. 
Transcranial Doppler is also capable of capturing signal through the thinner temporal bone 
to evaluate concussions or traumatic brain injury [36, 38-41].  Additionally, when cranial 
windows are employed and the skull is partially removed, invasive ultrasound imaging can 
be employed [42]. Despite these current limitations, pre-clinical studies are exploring ways 
to improve ultrasound brain imaging: by reducing ultrasound probe size for implantation, 
by developing improved US beamforming techniques, and by optimizing ultrasound 
imaging for guidance during neurosurgery [43, 44]. 
1.4 Photoacoustic imaging and applications in the brain 
Photoacoustic (PA) imaging is an established imaging method based on properties 
of light and sound. PA imaging uses light to interrogate a target of interest. The irradiated 
region absorbs light and subsequently undergoes thermal expansion which produces 
transient photoacoustic waves [45, 46]. The produced acoustic wave is localized and 
dependent on the optical properties of the irradiated volume. The resulting acoustic 
pressure wave (2) can be described by the optical absorption coefficient of the irradiated 
target (µa, cm-1), the light fluence (F, J/cm2), and the Grüneisen parameter (Γ), which is a 
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temperature dependent variable that accounts for volume expansion, specific heat, and the 
speed of sound [47].  That is,  
𝑝0 =  µ𝑎 · 𝐹 · 𝛤 (2) 
 
Because of the dependence of the photoacoustic wave on the absorption properties 
and light fluence used to irradiate a material of interest, medical photoacoustic imaging is 
contingent upon the optical properties of tissue. To reduce scattering and increase depth 
penetration into the tissue, light in the near-infrared (NIR) range is used (Figure 1) [48]. 
This comprises of wavelengths between 600-1200 nm and allows for PA imaging of 
endogenous absorbers of the tissue as well as exogenous absorbers, i.e., PA contrast agents 
[49]. 
 
Figure 1. The first and second optical windows, NIR-I and NIR-II provide optimal 
wavelengths for in vivo photoacoustic imaging [49]. 
Photoacoustic imaging of endogenous absorbers such as deoxygenated and 
oxygenated blood, melanin, and fat can provide important functional information without 
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the need for additional contrast. By tuning the wavelength of light used to optimize for a 
specific endogenous absorbers’ optical spectrum, PA imaging can collect relevant 
information about physiological properties such as oxygen saturation or skin cancer [50, 
51]. Although endogenous absorbers can help to uncover biological properties, exogenous 
photoabsorbers can be employed to further enhance contrast and allow for more advanced 
diagnostic imaging [52]. Exogenous contrast agents typically include dyes and 
nanoparticles (NPs) [52, 53]. There are a wide variety of NPs which are capable of being 
synthesized in various sizes with surface modifications and functionalized for molecularly 
specific imaging [54, 55]. By altering nanoparticle size and shape, NPs can often be 
synthesized at a specific wavelength to optimize their PA contrast while reducing contrast 
caused by background endogenous absorbers [47]. In addition, PA imaging has the 
capability to image and identify multiple distinct photoabsorbers at once. This process is 
performed by analyzing acoustic waves received at various excitation wavelengths 
followed by spectral unmixing techniques used to resolve the photoabsorbers, exogenous 
and endogenous, within the region of interest [56].   
The unique characteristics of PA imaging allow it to be a purposeful tool for 
neuroimaging. Because of PA imaging’s dependence on optical absorption, it transmits 
light that is mostly ignored by bone to interrogate tissue, an advantage over other current 
CNS imaging modalities [57]. As a result, PA neuroimaging has been able to make use of 
a wide range of PA imaging methods such as spectroscopic PA, PA tomography, and PA 
microscopy [58-62]. For example, PA tomography has been used to visualize cerebral 
vessels and measure oxygen saturation, which has been further applied to functional 
imaging studies [63, 64]. Additionally, PA imaging has been used to detect targeted 
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nanoparticles in a brain tumor of a mouse model [65]. In PA microscopy, amyloid plaques, 
a hallmark of Alzheimer’s, were detected in vivo through a cranial window [66].  
As a result, PA neuroimaging has the potential to encompass a wide range of 
applications. Used in conjunction with US imaging, both morphological and functional 
information can be discerned. Furthermore, the two modalities are cost-effective, portable, 
and easily integrated as they can utilize the same US sensor and receiver electronics. 
Neither modality uses ionizing radiation, making them safer than those that do, such as CT, 
PET, and SPECT [67, 68]. Therefore, combining these synergistic modalities allows for 
real-time and effective neuroimaging.  
1.5 Perfluorocarbon nanodroplets (PFCnDs) 
Perfluorocarbon nanodroplets (PFCnDs) are a class of phase change agents that 
have been primarily investigated for contrast enhanced ultrasound imaging [69]. They are 
presented as an alternative to contrast enhanced imaging with microbubbles [69]. PFCnDs 
are attractive due to their triggered phase change ability from liquid nanodroplet to gas 
microbubble. As such, they present themselves as a versatile tool not only for imaging but 
also for localized delivery and opening of biological barriers [70, 71]. 
1.5.1 General characteristics 
PFCnDs are unique particles in that, when activated by laser or acoustic energy, 
can phase change from liquid to gas [72, 73]. As a result, and unlike microbubbles, their 
contrast is localized to the area in which they are activated [30, 74]. In addition, their 
circulation time is much longer than that of microbubbles, making them useful in longer 
 9 
imaging and therapeutic sessions [30].They are composed of a liquid core, a shell, and 
when activated via laser energy, an optical trigger [72, 75]. For laser activation, this optical 
trigger is key, as the laser interaction with the trigger causes an increase in local 
temperature and an acoustic pressure wave which together synergistically enable the 
droplet phase change [72]. Both acoustically activated and laser-activated PFCnDs behave 
similarly with regard to their phase change ability. In particular, phase change of PFCnDs 
results in a volumetric expansion of the PFCnDs to a gas microbubble on the order of four 
to five times the original diameter [76]. Additionally, phase change behavior for both 
acoustically activated and laser-activated PFCnDs is governed by their composition, the 
species of perfluorocarbon used and the droplet size, as well as energy parameters used, 
such as peak negative pressure for acoustic activation and light fluence for laser-activated 
droplets [73, 75, 77].    
The physical mechanism of PFCnD phase change is not well understood, although 
a few hypotheses have been considered, focusing on the thermodynamics and kinetics of 
the perfluorocarbon core [78, 79]. One theory relies on Laplace pressure, suggesting that 
PFC droplets become superheated when synthesized on the nanoscale, shifting their 
equilibrium saturation curve to higher temperatures and lower pressures. As a result, 
PFCnDs remain stable at temperatures and pressures in which they should 
thermodynamically vaporize [79]. Another theory posits that suppression of droplet 
vaporization at thermodynamically expected temperatures and pressures is due to kinetics. 
That is, PFCnDs are homogeneously nucleated and require considerable activation energy 
to phase change, resulting in superheated, kinetically metastable PFCnDs. Thus, 
spontaneous vaporization within the droplet population would be minimal [78]. 
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Composition and synthesis of PFCnDs have been explored extensively [30, 76, 80-
82]. Various perfluorocarbon cores have been utilized, with the primary focus on 
perfluorohexane (C6F14 – boiling point 57 ºC), perfluoropentane (C5F12 – boiling point 29 
ºC), and perfluorobutane (C4F10 – boiling point -2 ºC) for PFCnD synthesis [76, 83]. 
Biocompatible shells such as lipid and albumin have been used in addition to polymer and 
fluorosurfactant shells [30, 80, 82, 84]. In the case of laser-activated PFCnDs, optical 
triggers have covered a wide variety of optically absorbing particles, from organic dyes to 
metallic nanoparticles [30, 80, 85-87]. Furthermore, methods of synthesizing small, 
monodisperse droplet populations have been developed. Microfluidics, co-solvent 
evaporation techniques, the ouzo method, microbubble condensation, extrusion, and 
sonication and centrifugation are employed [76, 87]. Overall, a wide variety of materials 
and methods can be used to generate PFCnDs for biomedical applications.   
1.5.2 Applications of PFCnDs 
Biomedical applications of PFCnDs are far-reaching, with use in both imaging and 
therapy. As an imaging agent, PFCnDs are capable of providing diagnostic information. 
For example, PFCnD shells can be modified to include targeting ligands for molecular 
imaging [79, 88, 89]. Examples include vascular targeting or HER-2 targeting for cancer 
detection [82, 89]. Furthermore, PFCnDs can be combined with custom imaging sequences 
to improve image contrast, and the distinct behavior of droplets can be tracked to achieve 
super-resolution imaging [74, 85, 90, 91]. Although contrast enhancement and diagnostic 
capabilities can be achieved with acoustically activated droplets, laser-activated PFCnDs 
provide additional advantages. For laser-activated PFCnDs, the interaction of the optical 
trigger and laser allows laser-activated PFCnDs to act both as an ultrasound (US) and 
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photoacoustic (PA) contrast agent [30, 74]. Ultrasound and photoacoustic (US/PA) 
imaging of PFCnDs can provide localized, functional, and morphological imaging from 
the PA and US generated PFCnD signals [30, 74]. Although the skull can provide some 
challenges to US imaging, US and PA work together to overcome these potential gaps in 
functional imaging. In addition, PFCnD signal is dynamically captured in both US and PA 
imaging, and the unique characteristics of these particles can be exploited in the process of 
developing US/PA image-guidance of CNS barrier opening and delivery of cargo. 
Therapeutic applications of PFCnDs have been widely investigated since the early 
2000s [92]. By encapsulating cargo within a PFCnD and locally releasing it via the phase 
change triggered by acoustic or laser energy, PFCnDs can reduce unwanted effects from 
systemic release while increasing therapeutic efficacy [93]. Cargo loading is primarily 
contained to the PFCnD shell, as the perfluorocarbon core of the droplet is both 
hydrophobic and lipophobic [94, 95]. Therapeutic delivery using PFCnDs has been 
demonstrated with delivery of doxorubicin for cancer treatment as well as delivery of gases 
such as oxygen to the tissue [70, 71]. Transfection of genes has also been enhanced by the 
use of PFCnDs by delivering gene therapy agents via targeted PFCnD constructs [71]. 
The ability of PFCnDs to cavitate can also be used as a means of non-thermal 
therapy. Phase change nanodroplets have been used in applications such as tumor ablation 
and sonothrombolysis as well as more recently for sonoporation [71]. In neuroscience 
applications, acoustically activated PFCnDs have been used to open the BBB [96]. As 
laser-activated PFCnDs share similar behavior to acoustically activated PFCnDs, 
exploration of laser-activated PFCnDs to do the same is warranted. In particular, laser 
activation of PFCnDs is possible with higher boiling point species that would require 
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significantly high acoustic pressures to vaporize [76]. Thus, neuroscience applications 
using laser activation can utilize higher boiling point PFCnDs, reducing in vivo 
spontaneous vaporization that can occur with PFCs with boiling points lower than 
physiological temperature [70]. For example, when a high boiling point perfluorocarbon 
core is used, such as perfluorohexane (PFH), droplets transiently vaporize and recondense 
[74]. This characteristic nature of laser-activated PFHnDs to continuously phase change, 
i.e., expand and contract, can therefore be harnessed to open the BBB similar to cavitation 
and acoustic vaporization of PFCnDs with focused ultrasound.  
Consequently, the unique characteristics of laser-activated PFCnDs as an US/PA 
imaging and therapeutic agent support the investigation of laser-activated PFCnDs in 
neurological applications, specifically for BBB opening and US/PA neuroimaging.  
1.6 Summary of research goals 
The objective of this research is to develop laser-activated perfluorocarbon 
nanodroplets for applications in neuroscience. The versatility of laser-activated PFCnDs 
enables them to act as a multifaceted tool. PFCnDs can act as a mechanical agent to open 
biological barriers, a delivery vehicle, and a dual ultrasound and photoacoustic imaging 
contrast agent. The capabilities of laser-activated PFCnDs in the context of the brain is 
explored through these studies, and the usefulness of PFCnDs as mechanical agent, 
delivery vehicle, and US/PA imaging contrast agent is shown.  
In CHAPTER 2, laser-activated perfluorohexane nanodroplets are investigated as 
a noninvasive means to open the blood brain barrier. BBB opening is evaluated through 
Evans Blue dye extravasation into the tissue along with histology and 
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immunohistochemistry. Ex vivo ultrasound and photoacoustic imaging after BBB opening 
is also demonstrated and establishes PA imaging after BBB opening as a means for 
evaluating the extent of BBB opening caused by laser-activated PFHnDs. CHAPTER 3 
continues to examine laser-activated PFHnD induced BBB opening by evaluating the laser 
parameter effects on the extent of BBB opening. Qualitative and quantitative analyses are 
performed to understand how laser fluence and number of laser pulses used influences 
BBB opening area and volume.  
After the laser-activated PFHnD BBB opening is optimized for safety and efficacy, 
delivery of extravascular PA contrast agents to the brain for in vivo US/PA imaging is 
investigated. CHAPTER 4 determines the optimal PA contrast agents for short term and 
long term US/PA imaging studies through the use of in vitro cell studies. CHAPTER 5 
addresses in vivo US/PA imaging capabilities after laser-activated PFHnD induced BBB 
opening. In vivo imaging is shown to provide the ability to monitor the extent of BBB 
opening over time. In addition, PFCnDs are evaluated for their ability to provide dynamic 
US/PA imaging contrast in the brain. Specifically, a set of laser-activated perfluoropentane 
nanodroplets is delivered to the brain post BBB opening to examine multiplexed delivery 
of PA imaging contrast. 
Finally, CHAPTER 6 discusses the conclusions drawn by investigating laser-
activated PFCnDs for neurological applications and comments on the future work to be 
completed with this nanoagent. First, challenges of the current studies are addressed and 
next steps are presented. Next steps, ranging from utilizing laser-activated PFCnDs to open 
other biological barriers to longitudinal US/PA neuroimaging are described, providing an 
overall outlook for laser-activated PFCnDs in neuroscience.  
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CHAPTER 2. NON-INVASIVE BLOOD BRAIN BARRIER 
OPENING USING LASER-ACTIVATED PERFLUOROCARBON 
NANODROPLETS  
2.1 Introduction 
Noninvasive treatment and monitoring of neurological disease is greatly hindered 
by the blood brain barrier (BBB), which often blocks delivery of therapeutics and contrast 
agents to the brain tissue [9, 97]. To overcome this barrier, many methods of delivering 
contrast and therapeutics to the brain for disease diagnosis and treatment have been 
developed and are currently used in the clinic [5, 6, 9]. However, the methods developed, 
such as surgical resection, device implantation, or chemical manipulation of tissue via 
pharmacological substances, have challenges and pitfalls. These methods can be invasive, 
and their effects can result in widespread opening of the BBB, which is not always 
desirable, as this greatly increases the risk of complications such as infection [5, 9]. 
Furthermore, these interventions often do little to prevent the recurrence rate of high 
mortality diseases, like glioblastoma [6]. This main challenge of overcoming the BBB is 
difficult, as it prevents the passage of large molecules (>500 Da) from entering into the 
brain tissue [9, 97]. In recent years, focused ultrasound (FUS) has been developed as an 
alternative method to transiently open the BBB by using the interaction between the FUS 
field and microbubbles [5, 11, 18, 97, 98]. Although the biological mechanisms of this 
method are not fully understood, it is widely believed that the oscillation or cavitation of 
microbubbles, which interact with the endothelial lining of the brain vasculature, stretch 
tight junctions and increase the uptake through mechanotransduction pathways, allowing 
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for larger molecules to pass through the BBB [12, 97, 98]. Because of its localized effect, 
BBB opening occurs only where the FUS field and microbubbles are present, and delivery 
of contrast and therapeutic agents can be targeted to precise locations. FUS mediated 
delivery of therapeutics to the brain has shown promise, resulting in initial clinical trials 
[27, 99]. 
Another possible, noninvasive means of opening the BBB is through the use of 
perfluorocarbon nanodroplets (PFCnDs). PFCnDs are unique particles, that when activated 
by electromagnetic or acoustic energy, can phase change from liquid to gas [72, 73, 75]. 
They are composed of a liquid core, a shell, and when activated via laser light, an optical 
trigger [72, 75]. PFCnDs, activated by a FUS field and converted to gas microbubble in 
situ have been investigated to examine their ability to open the blood brain barrier [96, 
100]. Acoustically activated PFCnDs phase change to microbubbles when exposed to 
sufficient rarefractional pressure provided by FUS and are capable of providing BBB 
opening through the phase change and stable cavitation of the produced microbubbles [96]. 
Because of their similarity to microbubbles in their gaseous state, it was demonstrated that 
PFCnDs are capable of producing similar BBB opening effects [96, 100]. Although 
acoustic droplet vaporization (ADV) enables BBB opening, it involves the use of below 
body temperature perfluorocarbon such as perfluorobutane (boiling point -1.7°C) or 
octafluoropropane (boiling point -36.7°C) which can result in premature, spontaneous 
droplet vaporization in vivo [100]. These lower boiling point PFCs are used for acoustic 
droplet vaporization because PFCs with boiling points above body temperature would 
require potentially unsafe, higher pressure acoustic waves to cause phase change [73]. 
Thus, there are limitations to the use of ADV as a means to open the BBB. 
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In general, PFCnDs are multifaceted as they are small in size (i.e., hundreds of 
nanometers) in their liquid state and are capable of carrying therapeutics or other particles, 
which are either encapsulated or attached to the droplet shell [70]. More importantly, 
PFCnDs act as a versatile agent when activated to their gaseous phase via multiple forms 
of energy including electromagnetic waves such as pulsed laser light [73, 75, 80]. 
Specifically, the absorption of laser energy by the droplet’s optical trigger causes localized 
heating and expansion and produces a photoacoustic pressure wave, and together these 
phenomena phase change a PFCnD from liquid to gas [75]. Vaporization under a laser 
pulse of low and, therefore, safe fluence produces ultrasound (US) and photoacoustic (PA) 
contrast, resulting in the development of laser-activated PFCnDs as dynamic US and PA 
imaging contrast agents [30, 73, 75, 80, 90]. Laser activation of PFCnDs due to the optical 
trigger located within the droplet allows for implementation of higher boiling point 
PFCnDs, such as perfluoropentane (boiling point 29°C) or perfluorohexane (boiling point 
57°C) [83]. Thus, laser-activated PFCnDs can be synthesized with many different 
components, using varying combinations of photoabsorbers, perfluorocarbon (PFC) 
species, as well as PFCnD sizes, creating application-specific PFCnDs  [30, 75, 80, 86]. 
Laser-activated PFCnDs have the potential to aid in the diagnosis and treatment of 
neurological diseases. Indeed, optically activated PFCnDs are an attractive tool for BBB 
opening, as they can be selectively and repeatedly vaporized at the particular wavelength 
at which their optical trigger absorbs the most laser light energy [30, 75, 80]. To enable 
successful BBB opening, PFCnD parameters (size, PFC species, and concentration) and 
laser parameters (fluence and lasing duration) must be selected appropriately in order to 
achieve BBB opening.  
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In this work, the characteristics of NIR dye loaded perfluorohexane nanodroplets 
(PFHnDs) were harnessed to open the BBB and deliver substances to the tissue. BBB 
opening was evaluated qualitatively on both the macroscopic and microscopic level by 
examining Evans Blue extravasation, ex vivo US/PA imaging, and histology. 
2.2 Materials and methods 
2.2.1 Laser-activated perfluorohexane nanodroplet (PFHnD) synthesis 
With a boiling point being above body temperature (57°C), perfluorohexane 
(FluoroMed, L.P.) was used as the core of the synthesized PFCnDs [83]. In addition to 0.3 
mL of perfluorohexane (PFH), 3 mL 1X PBS, 1 mL Zonyl FSO fluorosurfactant (1% v/v, 
Sigma Aldrich), and 2 mg Epolight 3072 dye (Epolin, Inc.) – a near infrared (NIR) dye 
with a peak absorption around 1064 nm – were used. All materials were added to a 7 mL 
scintillation vial and vortexed for 10 seconds (Vortex Mixer, Fisher Scientific). The vial 
was placed in an ice bath and sonicated using a probe sonicator (Q500, QSonica LLC) for 
a total of 60 seconds at the lowest sonicator amplitude of 1. The emulsion was then 
transferred to two, 2 mL tubes and spun in a mini centrifuge (Mini-Spin, Eppendorf) at 400 
rcf for 2 minutes to remove excess dye and size separate PFHnDs. The supernatant 
containing smaller sized PFHnDs was transferred to another 2 mL tube and spun again at 
400 rcf for 4 minutes. To concentrate the droplets, the supernatant resulting from this 
second centrifugation step was removed and the pellet was resuspended in 0.5 mL 1X PBS 
using a water bath sonicator (VWR, 180 W). When preparing larger sized PFHnDs for 
BBB opening that would enable larger (i.e., micrometer) sized constructs to extravasate, 
droplets were sonicated and size separated as described above, but the pellet of the first 
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centrifugation step was kept, resuspended in 1 mL 1X PBS, and the supernatant discarded. 
For in vivo experiments, the droplets were left under UV light for 30 minutes for 
sterilization. A spectrophotometer (Evolution 220, Thermo Scientific) was used to measure 
the absorbance of PFHnDs both with and without NIR dye, and the blank droplet spectrum 
was subtracted from the spectrum of the PFHnDs containing NIR dye. Droplet zeta 
potential and size were measured in PBS using a dynamic light scattering (DLS) instrument 
(Zetasizer Nano ZS, Malvern Instruments Ltd.).  
2.2.2 US/PA imaging of a phantom containing laser-activated PFHnDs 
To evaluate droplet vaporization and recondenstation dynamics, a polyacrylamide 
phantom containing solely PFHnDs was fabricated. The polyacrylamide phantom was 
prepared by first adding 127 mL nanopure water (Thermo Scientific), 42.5 mL 40% 
polyacrylamide solution (VWR), and 1.7 mL 10% aqueous ammonium persulfate (Sigma 
Aldrich) to a Büchner flask and mixing with a magnetic stir bar and stir plate. The solution 
was degassed by sealing the top of the flask with a rubber stopper, attaching the flask to a 
vacuum, and sonicating using the water bath sonicator for 10 minutes. The solution was 
returned to the stir plate and 170 µL PFHnDs were added to the solution followed by 212.5 
µL of tetramethylethylenediamine (Sigma Aldrich). The phantom was poured into a plastic 
container and allowed to solidify before removal from the mold. 
2.2.3 Imaging and processing of laser-activated PFHnD vaporization and 
recondensation dynamics 
To visualize the phase change dynamics of PFHnDs, the prepared polyacrylamide 
phantom embedded with PFHnDs was imaged using a Verasonics Vantage 256 ultrasound 
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system (Verasonics Inc.) and an Nd:YAG Phocus laser (10 Hz, 5-7 ns pulse length, Opotek 
Inc.) operating at 1064 nm and a fluence of 46 mJ/cm². An array transducer operating at 5 
MHz (L11-4v, Verasonics Inc.) was used to capture ultrasound at a frame rate of 500 
frames per second. Photoacoustic signal was captured at the rate of 10 Hz (laser PRF). 
Ultrasound data was collected for six frames after each laser pulse (12 milliseconds total), 
and pixels containing droplets were identified using compounded harmonic ultrasound 
difference images, similar to a previously described method [91]. To visualize PFHnD 
recondensation dynamics over time, linear ultrasound intensity of the identified droplet 
pixels was plotted over multiple laser pulses.  
2.2.4 Laser-activated PFHnD induced blood brain barrier opening 
All animal studies were conducted under the protocol approved by the Institutional 
Animal Care and Use Committee at Georgia Institute of Technology. Prior to anesthesia, 
an injection of sustained released buprenorphine (IP, 0.8 mg/kg) was administered to each 
animal (C57BL/6 mouse). Mice were anesthetized using a combination of isoflurane (2%) 
and oxygen (0.6 L/min). Mice were positioned in a stereotax in the prone position, on a 
heating pad (Stoelting Co). Hair from the scalp was removed through shaving and 
depilatory cream. Proparacaine (0.5%, Henry Schein) was applied to the eyes and a retro-
orbital injection of 50 µL of 3% w/v sterile filtered Evans Blue (EB) (Sigma Aldrich) was 
administered with or without a co-injection of 50 µL PFHnDs (~108 droplets, measured 
using a Malvern NanoSight NS300), depending on the animal group. The animal groups 
included mice irradiated with 1064 nm light and co-injected with EB dye and PFHnDs 
(experimental group, n=10), mice irradiated with 1064 nm light and injected with EB dye 
only (i.e., no PFHnDs, control group, n=3), and mice co-injected with EB dye and PFHnDs 
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but not irradiated (another control group, n=3). Animals were positioned beneath an 
unfocused 1.5 mm core diameter optical fiber (0.39 NA, Thorlabs, Inc.) to enable 
irradiation of the right side of the brain. Irradiation was performed using a Vibrant laser 
(10 Hz, 5-7 ns pulse length, Opotek Inc.) with a wavelength of 1064 nm and a fluence of 
70 mJ/cm². Irradiation was performed for 60 seconds, falling within a similar time range 
to that of sonication for microbubble assisted FUS BBB opening (Figure 2) [5, 17]. After 
laser irradiation, mice were observed for 4 hours, with no gross behavioral damage 
observed. Animals were then sacrificed and perfused with 1X PBS (pH 6.8) followed by 
4% paraformaldehyde (PFA). Heads were removed and post-fixed overnight in 4% PFA 






Figure 2. Laser irradiation setup for blood brain barrier (BBB) opening. (A) View of the 
optical fiber placed above the mouse stereotax and heating pad. (B) Optical path of the 
laser beam to the optical fiber. (C) Laser system used for BBB opening and its 
specifications. 
 
Figure 3. Timeline for laser-activated PFHnD induced BBB opening procedure and 
evaluation. 
2.2.5 Ex vivo ultrasound and photoacoustic imaging 
Fixed, excised mouse brains were imaged using a photoacoustic and ultrasound 
imaging system (Vevo LAZR, FUJIFILM VisualSonics Inc.) with a 40 MHz ultrasound 
and photoacoustic imaging probe (LZ-550, FUJIFILM VisualSonics Inc.). The system’s 
tunable Nd:YAG laser (20 Hz, 5-7 ns pulse length) was operated at a wavelength of 1064 
nm and at a fluence of 10-12 mJ/cm², and specimens were imaged at a US/PA frame rate 
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of 5 frames per second. Tissue samples were placed on top of an 8% gelatin base in a 
container filled with degassed water. Images were acquired by performing coronal and 
sagittal 3D US/PA imaging with a distance step size of 0.1 mm. 3D US/PA imaging at 
1064 nm was performed both for the experimental and two control groups.  
2.2.6 Histology and immunohistochemistry 
After remaining in 4% PFA solution for 24 hours at 4°C, brains were transferred to 
a solution of 30% sucrose and stored at 4°C for 5 days. Brains were snap frozen, and 20 
µm coronal sections were cut using a cryostat (Leica CM 1860, Leica Biosystems). For 
each brain, 72 sections were cut and analyzed, spanning a total volume of 1.44 mm. 
Standard hematoxylin (Sigma Aldrich, Gill No.2) and eosin (VWR) (H&E) staining was 
performed. H&E photomicrographs were captured using the bright field mode of a Zeiss 
AxioObserver Z1 Microscope. IHC was also performed using DAPI (4',6-diamidino-2-
phenylindole, Invitrogen) and a secondary antibody of goat anti-mouse IgG (H+L) tagged 
with Alexa Fluor 488 (Invitrogen). IHC photomicrographs were captured using a Zeiss 
Laser Scanning Confocal Microscope 700. 
2.3 Results 
2.3.1 Characterization of laser-activated PFHnDs 
The results of PFHnD characterization including size, absorbance, charge, and 
dynamic ultrasound behavior are shown (Figure 4). The synthesized PFHnDs had a 
diameter of 340 nm ± 170 nm (Figure 4A), an order of magnitude smaller than typical 
microbubbles used for BBB opening [97]. Due to optical NIR dye embedded into PFHnDs, 
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the droplets exhibit peak optical absorption at around 1064 nm (Figure 4B). A dye 
absorbing near the 1064 nm wavelength was specifically selected because of the deep 
penetration of light in tissue at this wavelength, readily available from an energy-efficient 
nanosecond pulsed laser system [75]. Evans Blue had a peak optical absorption of 600 nm, 
thus there was minimal optical interaction between the 1064 nm light from the Nd:YAG 
laser and Evans Blue dye. A fluorosurfactant shell was used to encapsulate liquid PFH and 
the NIR dye, resulting in a droplet with a negative zeta potential when measured in PBS  
(-21 mV, Figure 4C).  
 
The synthesized PFHnDs produced a repeatable vaporization and recondensation 
response to pulsed laser irradiation (Figure 4D). This liquid-gas-liquid phase change 
dynamic is shown via the linear ultrasound intensity of a PFHnD over time and for multiple 
laser pulses, with dashed lines indicating time between acquisitions. In the presence of laser 
irradiation, PFHnDs quickly change from liquid to gas, denoted by an increase in 
ultrasound amplitude. During this phase change process, PFHnDs expand to 4-5 times their 
droplet size, making these particular droplets 1-2 µm in size in their gaseous sate [72]. 
After 10 milliseconds, the PFHnD recondenses, resulting in a lower observed ultrasound 
intensity. This vaporization and recondensation cycle is repeated every 0.1 seconds, which 
corresponds to the laser PRF of 10 Hz. As a result, laser activation of PFHnDs enables the 




Figure 4. Characterization of perfluorohexane nanodroplets (PFHnDs).  
(A) Size distribution of droplets (340 nm ± 170 nm). (B) Normalized absorbance spectra 
of droplets containing a near-infrared (NIR) dye with a peak absorption at 1064 nm and 
Evans Blue dye with a peak optical absorption at 600 nm, both of which are used for in 
vivo experiments of blood brain barrier opening. Images to the right show appearance of 
Evans Blue and NIR dye loaded PFHnDs. (C) Zeta Potential of the fluorosurfactant shell 
of the PFHnDs, with a peak at -21 mV. (D) Normalized ultrasound signal produced by 
PFHnDs as they repeatedly vaporize in response to pulsed laser irradiation and then 
immediately recondense after each laser pulse. 
2.3.2 Evans Blue staining confirms BBB opening via laser-activated PFHnDs 
Validation of BBB opening was confirmed through visual examination of EB dye 
staining, US/PA imaging, and histology. EB dye extravasation was evaluated through 
inspection of the whole brain followed by inspection of coronal cross-sections for each 
animal group (Figure 5). The differences in brain tissue coloration results from the lighting 
in which images were taken. EB dye is a commonly used substance for determining BBB 
opening, as it attaches itself to albumin and will cross the BBB only when the barrier has 
been opened [101]. When Evans Blue dye has extravasated, it is visibly evident in the 
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tissue. After laser irradiation, EB dye was allowed to extravasate for four hours prior to 
animal perfusion, as the BBB likely begins to close at this time point [5, 102]. For the 
experimental group, when EB dye was co-injected with PFHnDs and the laser irradiation 
was applied, EB dye extravasation into tissue is apparent in both whole brain and coronal 
cross section images (Figure 5A-B). This staining is located on the right side where the 
pulsed laser irradiation was applied. It appears greatest at the top of the brain corresponding 
to where laser fluence is the highest. However, when EB dye and PFHnDs were co-injected 
and no laser irradiation was applied, the brain tissue remains unstained (Figure 5C-D). 
Finally, the combination of laser irradiation and EB dye administration but no injection of 
PFHnDs also results in tissue with no EB dye extravasation (Figure 5E-F). Thus, these 
results demonstrate that PFHnDs combined with laser irradiation are capable of opening 




Figure 5. Photographs of Evans Blue (EB) dye extravasation into tissue. (A-B) Whole 
brain (top view) image and coronal cross-section of brain showing EB dye leakage into 
brain tissue post-irradiation. The rounded dashed contour highlights area of EB dye 
extravasation and the horizontal dashed line indicates the location of the coronal cross 
section displayed in panel B. (C-D) Control: whole brain image and coronal cross section 
of brain with EB dye and droplets administered but no laser irradiation applied. Without 
laser irradiation, EB dye is unable to extravasate across the blood brain barrier, preventing 
tissue staining. (E-F) Control: whole brain image and coronal cross-section of brain with 
laser irradiation applied and EB dye administered but no droplets injected. Without 
droplets, EB dye is unable to extravasate across the blood brain barrier, preventing tissue 
staining. Reprinted from [84]. 
2.3.3 US/PA imaging of extravasated photoacoustic dye  
US/PA imaging of perfused, excised murine brains was also performed to evaluate 
BBB opening (Figure 6). The synthesized PFHnDs contain a dye absorbing at 1064 nm, 
which produces a PA signal at that wavelength. Thus, if droplets containing the dye empty 
some of their cargo in the process of vaporization, this dye has the potential to extravasate 
across the BBB. Once extravasation has occurred, PA signal at 1064 nm should be present, 
allowing for US/PA imaging of the tissue. US imaging provides an anatomical map, while 
PA imaging provides the localized signal of extravasated dye. In the experimental group 
 27 
(Figure 6A), where PFHnDs and laser irradiation were present during the BBB opening 
procedure, PA signal is present on the right side of the brain in a coronal cross section that 
corresponds to the location of EB staining as seen in the whole brain and cross section 
photographs (Figure 5A-B). To confirm that the PA signal comes from the 1064 nm 
absorbing dye extravasated post-laser irradiation, control groups were also US/PA imaged 
at 1064 nm. One control group involved the administration of droplets but no laser 
irradiation during the BBB opening procedure (Figure 6B). The second control group 
included laser irradiation but no administration of droplets (Figure 6C). US/PA imaging of 
these brains demonstrates that extravasation of dye occurs only if droplets are present and 
have been irradiated because no PA signal at 1064 nm is produced otherwise (Figure 6B-
C). Thus, US/PA imaging can be used to evaluate BBB opening when laser-activated 





Figure 6. Ex vivo photoacoustic and ultrasound (US/PA) imaging of murine brains  
(A) US/PA imaging of an animal with blood brain barrier opening and release of near-
infrared (NIR) dye from PFHnDs after laser irradiation. After opening, the NIR dye has 
extravasated across the blood brain barrier and provides signal when imaged at 1064 nm. 
(B) Control: US/PA imaging demonstrating that without laser irradiation to vaporize 
droplets, no NIR dye has extravasated, resulting in no PA signal produced at the imaging 
wavelength. (C) Control: US/PA image demonstrating that without droplets to open the 
blood brain barrier, no NIR dye has extravasated, resulting in no PA signal produced at the 
imaging wavelength. Reprinted from [84]. 
2.3.4 Histological and immunohistochemical evaluation of laser-activated PFHnD 
induced BBB opening 
BBB opening was further examined on the cellular level using histological and 
immunohistochemical methods (Figure 7). For these studies, larger size PFHnDs were 
synthesized (837 nm ± 229 nm) to ensure significant BBB opening and enable definitive 
extravasation of biological particles across the BBB. When activated via laser irradiation, 
these PFHnDs should expand to 3-4 µm in size in their gaseous sate [72]. As a result, these 
larger bubbles will enable greater BBB opening and illicit a larger biological response [21]. 
For the studies involving laser irradiation (Figure 7A-C, G-I), irradiation was performed 
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for 60 seconds at a wavelength of 1064 nm and a fluence of 70 mJ/cm2. To examine the 
extravasation of nanosized constructs, fluorescence images captured the extravasation of 
mouse immunoglobulin G (IgG),  which  should only cross the BBB when the barrier is 
opened, due to its width being 13.7 nm (Figure 7A-B, D-E, G-H) [103]. In the experimental 
group where opening took place (laser irradiation and droplets), staining of IgG is clearly 
present (Figure 7A-B). In control animals where no laser irradiation was applied but 
droplets were administered (Figure 7D-E), no extravascular IgG is observed. However, 
there appears to be low levels of IgG signal in the lateral ventricles in the fluorescent image 
of the whole brain (Figure 7D), but when a high magnification view of the tissue is 
examined (Figure 7E), no IgG is present. In the case of laser irradiation but no droplet 
injection, low levels of IgG are also observed in both the whole brain image and magnified 
view (Figure 7G-H). From the IHC analysis, it appears that some IgG may be present in 
the control groups, however, delivery of IgG across the BBB is most obvious in the 
experimental group containing both laser irradiation and PFHnDs.  
Delivery of larger constructs, specifically red blood cells (RBCs), was also 
examined via H&E staining (Figure 7C, F, I). As seen in the experimental group (Figure 
7C), RBCs extravasated across the blood brain barrier and are highlighted by the tissue 
area stained red. For both controls, however, no RBCs extravasated (Figure 7F, I). Because 
RBCs were able to extravasate in the experimental group, the result indicates that laser-
activated PFHnDs were able to create openings in the BBB that allowed for 6 µm diameter 
particles to cross the blood brain barrier [104].   
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Figure 7. Immunohistochemical and histological analysis of mouse brain tissue.  
(A-B) Immunohistochemical (IHC) staining of DAPI and secondary antibody IgG of a 
mouse treated with both droplets and laser irradiation on the right side of the brain. 
Presence of green fluorescence (white arrows) demonstrates IgG extravasation and opening 
of the blood brain barrier. (C) Hematoxylin and eosin (H&E) staining of a mouse treated 
with both droplets and laser irradiation. Presence of red blood cells is indicated by bright 
red eosin staining (black arrows) and demonstrates extravasation and opening of the blood 
brain barrier. (D-E) Control: IHC staining of a mouse treated with droplets only and no 
laser irradiation. (F) H&E staining of a mouse treated with droplets only and no laser 
irradiation. (G-H) Control: IHC staining of a mouse treated with laser irradiation but with 
no droplets injected. (I) H&E staining of a mouse treated with laser irradiation but with no 
droplets injected. (A),(D),(G) are fluorescence images displaying the entire 20 µm tissue 
slice while (B-C), (E-F), and (H-I) display a close-up view of the tissue section. Reprinted 
from [84]. 
2.4 Discussion 
In this work, successful delivery of various sized constructs such as RBCs, Evans 
Blue (EB) visible dye bound to albumin, NIR dye, and IgG was delivered across the BBB 
using laser-activated perfluorohexane nanodroplets (PFHnDs). The delivery of these 
particles was verified and evaluated through different methods including EB dye staining, 
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US/PA imaging, and histological tissue analysis. Thus, droplet parameters play a key part 
in determining BBB opening. Specifically, droplet size, PFC species, and photoabsorbers 
selected all play a unique role in the effective size and spread of BBB opening and therefore 
delivery of substances into the tissue. For example, larger sized PFCnDs can cause an 
increase in BBB opening volume and potentially damage to the tissue. A lower boiling 
point perfluorocarbon that does not repeatedly vaporize and recondense such as 
perfluoropentane may not open the BBB to a similar extent as PFH. Further, a lower 
wavelength photoabsorber could prevent deeper activation of PFCnDs due to reduced light 
penetration in the tissue. Thus, by selectively choosing the appropriate droplet components, 
droplets can be used in and tailored to a diverse set of applications, including delivery of 
contrast agents and therapeutics to the brain. Furthermore, laser parameters also contribute 
to BBB opening and can be adjusted based on droplet parameters to achieve the desired 
volume and location of BBB opening in the brain tissue.  
In these studies, PFCnD characteristics were chosen to achieve effective BBB 
opening. Specifically, PFHnDs were synthesized such that upon laser irradiation, the size 
of resulting microbubbles would be similar to those that have been used in FUS BBB 
opening (Figure 4A) [5]. A NIR dye absorbing near 1064 nm was used not only for 
increased depth penetration of light but also to avoid optical absorption by the Evans Blue 
dye co-injected with PFHnDs. Evans Blue has a peak absorption of 600 nm, and at 1064 
nm, EB absorption is negligible (Figure 4B). Therefore, the negligible interaction of EB 
and the 1064 nm laser light will not cause BBB opening, and extravasation of the EB across 
the BBB will only occur when droplets are both present and exposed to laser irradiation. 
In addition, low EB absorption at 1064 nm indicates that the captured US/PA signal is 
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produced from NIR dye delivered to the tissue. The US/PA imaging of the NIR dye in 
comparison to Evans Blue photographs also suggests that different sized particles are able 
to cross the BBB using laser-activated PFHnD opening (Figure 6A).  
Furthermore, the PFC species used in these droplets plays a key role in successful 
BBB opening. The ability of PFHnDs to repeatedly vaporize under pulsed laser excitation 
and then recondense potentially makes a PFH droplet core more attractive than lower 
boiling point PFCs such as perfluorobutane or perfluoropentane [83]. The reactivation of 
PFHnDs over multiple laser pulses suggests that in combination with an increased number 
of laser pulses used, lower concentrations of PFHnDs could be used to open the BBB, 
reducing the injected PFHnD dose. This concentration comparison may also extend to 
microbubble concentrations used in FUS BBB opening. Based on the rapid expansion and 
recondensation of PFHnDs, it is supposed that the phase changing droplets interact with 
the BBB similar to the way microbubbles do in a FUS field (Figure 4D). As PFCnDs have 
a longer circulation time than microbubbles (i.e., hours vs. minutes, respectively), fewer 
PFHnDs may be needed to achieve effective BBB opening [70]. As a result, PFC choice 
plays a key role when designing laser-activated PFCnDs for BBB opening.  
To examine BBB opening, EB staining was evaluated grossly and supported the 
hypothesis that BBB opening would only occur where both laser irradiation and PFHnDs 
are present (Figure 5). Ex vivo US/PA imaging was also performed to co-register PA signal 
with the area of EB staining, both localized to the right side of the brain (Figure 6). US/PA 
contrast from delivered NIR dye indicates the potential for future in vivo US/PA imaging 
of laser-activated PFCnD during BBB opening and delivery of PA contrast agents. Finally, 
histological staining analysis was completed to examine the effect of laser-activated 
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PFHnD opening on the molecular level. Overall, extravasation was greatest in the 
experimental group (Figure 7A-C), further demonstrating that BBB opening can be 
achieved using laser-activated PFHnDs. However, in both control groups (Figure 7D-E, G-
H), IgG signal is present.  For the control group where PFHnDs were injected but no laser 
irradiation was applied, IgG signal was visible in the lateral ventricles but not in a 
magnified view of the brain tissue, suggesting that the signal most likely corresponds to an 
incomplete perfusion. In the control group with laser irradiation and Evans Blue dye but 
no PFHnDs administered, there are a few possibilities as to why IgG may be present. Both 
deoxygenated hemoglobin and oxygenated hemoglobin absorb in the NIR wavelength 
range and as a result, interaction of the blood with laser energy could cause small openings 
in the BBB that would allow for IgG to cross the BBB [105]. Additionally, incomplete 
perfusion of the tissue could also cause a false positive fluorescence in the sample, as there 
appears to be IgG signal coming from the lateral ventricles (Figure 7G) in addition to 
fluorescence signal seen in the magnified view of the pictomicrograph (Figure 7H). Despite 
the fluorescence signal seen in both control samples, IgG signal is greatest in the 
experimental group showing that localized BBB opening is effective when PFHnDs are 
irradiated via pulsed laser excitation. Overall, the results of the methods used to evaluate 
BBB opening (i.e., EB staining, US/PA imaging, and histological tissue analysis), support 
the hypothesis that laser-activated PFCnDs are capable of opening the BBB. 
Not only can droplets cause opening of this particular biological barrier, but they 
also have the potential to be implemented to open other biological barriers that may be 
otherwise inhibited and prevent effective, non-invasive treatment. In particular, another 
barrier that poses challenges in noninvasive delivery is the blood spinal cord barrier 
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(BSCB) [4]. Recently, the BSCB has been opened using FUS and microbubbles, so 
investigation into the ability of PFCnDs to open the BSCB is warranted [4, 106]. For 
opening of both the BBB and BSCB, laser and droplet parameters should be evaluated for 
safety and efficacy, as opening of these barriers without fully optimized parameters has the 
potential to damage tissue.  
In addition, droplets can be synthesized to as small as 100-200 nm and therefore 
have the potential to extravasate themselves when the BBB has been opened [76, 107]. 
Thus, through the administration of one set of small, cargo carrying droplets and a set of 
larger droplets used for BBB opening, delivery of substances can be contained within cargo 
carrying PFCnDs until they have reached their desired location. Because droplets can be 
produced in various sizes and compositions, they are capable of performing as a 
multiplexed system, enabling subpopulations of droplets to perform different tasks. This 
multiplexed ability can be harnessed not only via size, but by also using photoabsorbers of 
different peak wavelengths, different core perfluorocarbons, and different shell 
compositions.  
Consequently, laser-activated droplet adaptability enables a platform for opening 
of the BBB and delivery of both therapeutics as well as imaging contrast agents to the 
brain. Furthermore, laser-activated droplets produce localized, temporally modulated 
ultrasound and photoacoustic contrast and therefore in the future could provide the 
opportunity for image-guidance of BBB opening as well as image-guidance of delivery of 
cargo to the tissue [30, 74, 85, 90, 91]. Because the process of optimized BBB opening is 
transient and reversible, localized delivery of cargo to the brain is reproducible, enabling 
the potential to treat or image longitudinally. From opening barriers to providing delivery 
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and imaging contrast, the presented studies provide an initial demonstration of the 
capabilities and potential of laser-activated PFCnDs in neurological applications. 
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CHAPTER 3. OPTIMIZATION OF LASER PARAMETERS FOR 
BLOOD BRAIN BARRIER OPENING INDUCED BY LASER-
ACTIVATED PERFLUOROCARBON NANODROPLETS 
3.1 Introduction 
A major challenge in the monitoring and treatment of various neurological diseases 
is the blood brain barrier (BBB) [97, 108]. The BBB is a physiological barrier that prevents 
large molecules (>500 Da) in the vascular system from extravasating to the brain tissue [9, 
97]. Due to the selective nature of the BBB, delivery of contrast agents or therapeutics is 
greatly hindered, making it difficult to monitor and treat neurological diseases [5, 15, 97, 
108, 109]. To overcome the BBB, various methods, such as surgical resection, device 
implantation, and chemical manipulation of the tissue are currently used [5, 9]. However, 
there are inherent risks with these methods including invasiveness and widespread opening 
of the BBB, increasing the potential for infection and resulting in limited success for 
treating diseases such as brain cancers, Alzheimer’s, and Huntington’s [6, 108]. Thus, the 
focus for monitoring and treatment of neurological diseases in the brain has shifted towards 
noninvasive measures, where BBB opening can be performed transiently, locally, and 
repeatedly [15, 97].  
One well-developed, noninvasive method of opening the BBB is microbubble-
assisted focused ultrasound (FUS) [11, 15, 97]. This method relies on the interaction of a 
focused ultrasound field and oscillating microbubbles to stretch endothelial tight junctions 
and increase uptake through mechanotransduction pathways, allowing larger molecules to 
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extravasate [12, 97, 98]. Microbubble-assisted FUS for BBB opening is a technique that 
has been evaluated for safety and efficacy [15-18]. FUS frequency, pulse duration, PRF, 
and pressure amplitude, as well as microbubble composition and dose have been examined 
to determine the optimal range of parameters [10, 19-26]. Consequently, this technology is 
used in applications ranging from small animal studies to clinical trials [27, 28]. 
Recently, perfluorocarbon nanodroplets (PFCnDs), a descendant of microbubbles, 
have been investigated as a means to transiently open the BBB [84, 96, 100]. PFCnDs are 
a phase change nanoagent capable of changing from liquid nanodroplet to gas microbubble 
when activated via acoustic or electromagnetic energy [72, 73, 75]. PFCnDs are comprised 
of a shell, perfluorocarbon core, and an optical trigger when activated via an optical energy 
source [75]. Specifically, laser-activated PFCnDs rely on the interaction between a pulsed 
laser and an optical trigger within the droplet to induce the phase change from liquid to gas 
[75]. Because perfluorocarbon itself is not optically absorbing, a highly optically absorbing 
dye or nanoparticle is encapsulated within the PFCnD to enable PFCnD vaporization. 
Phase change of the PFCnD occurs due to the localized heating and photoacoustic pressure 
wave that result from the optical trigger-laser interaction [75]. For laser-activated PFCnD 
induced BBB opening, perfluorohexane nanodroplets (PFHnDs) were investigated [84]. 
PFHnDs are attractive for use in BBB opening due to their ability to undergo repeated 
phase change from liquid to gas [74, 85, 90, 91], creating an oscillatory-like behavior and 
allowing laser-activated PFHnDs multiple opportunities to interact with the BBB and 
enable opening.  
In addition to enabling BBB opening, laser-activated PFCnDs are also capable of 
providing localized ultrasound (US) and photoacoustic (PA) image contrast [30, 73, 76, 
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80, 86]. The phase change of PFCnDs from liquid nanodroplet to gas microbubble provides 
US contrast while the pulsed laser-optical trigger interaction that initiates the phase change 
produces PA contrast. The unique US/PA image contrast provided by laser-activated 
PFCnDs allows for use in various in vivo applications from super resolution imaging to 
multiplexed imaging [30, 74, 82, 90]. Further, PFCnDs are capable of carrying cargo within 
the droplet or on the shell, making them attractive as controlled release delivery vehicles 
[70]. Their nanometer size also makes PFCnDs capable of extravasation across barriers 
such as leaky vasculature within a tumor or an opened BBB [70, 84, 87, 110]. As a result, 
the versatile nature of PFCnDs shows their potential to be utilized in a wide variety of 
applications including the central nervous system. 
To understand fully the capabilities of laser-activated PFCnDs in BBB opening and 
in neurological applications, it is necessary to study the effects of the laser parameters used 
to activate the PFCnDs. In these studies, two particular parameters, laser fluence and 
number of laser pulses used, were evaluated, with the results demonstrating how BBB 
opening can be controlled via laser-activated PFCnDs. 
3.2 Materials and methods 
3.2.1 IR-1048 laser-activated perfluorohexane nanodroplet synthesis and 
characterization 
IR-1048 perfluorohexane nanodroplets (PFHnDs) were synthesized using IR-1048 
dye (Sigma-Aldrich), perfluorohexane (PFH, FluoroMed, L.P.), and a lipid shell comprised 
of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-
2000] (DSPE-PEG(2000), 25 mg/mL, Avanti Polar Lipids, Inc.) and 1,2-distearoyl-sn-
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glycero-3-phosphocholine (18:0 PC (DSPC), 25 mg/mL, Avanti Polar Lipids). To create 
the lipid shell, 40 µL of DSPE-PEG(2000) and 8 µL of 18:0 PC (DSPC) were added to a 
10 mL pear-shaped flask (Sigma-Aldrich). An IR-1048 dye solution was prepared in 
chloroform (1mg/mL), and 200 µL was added to the flask. An additional 1 mL of 
chloroform was added to the flask to enable a smooth lipid cake. A rotary evaporator 
(Rotovapor, Büchi) was used at reduced pressure to remove the chloroform from the flask 
leaving an IR-1048 dye-coated lipid cake. The lipid cake was resuspended in 1 mL of PBS 
using a water bath sonicator (VWR, 180W). The solution was placed in a 7 mL scintillation 
vial, and 150 µL of PFH was added. The vial was vortexed for 10 seconds (Vortex Mixer, 
Fisher Scientific) and sonicated for five minutes in an ice-cold water bath (VWR, 180 W). 
The PFHnD solution was transferred to a 2 mL centrifuge tube and centrifuged for 60 
seconds in a mini-centrifuge (Mini-Spin, Eppendorf) to remove excess PFH and IR-1048 
dye. The supernatant was transferred to a new 2 mL centrifuge tube, and the pellet was 
discarded. Prior to in vivo experiments, droplets were left under UV light for 30 minutes 
for sterilization. 
PFHnD size and zeta potential were measured in PBS (pH 7.4) using a dynamic 
light scattering instrument (Zetasizer Nano ZS, Malvern Instruments Ltd.). To generate the 
absorbance spectrum of IR-1048 PFHnDs, a spectrophotometer was used to measure IR-
1048 PFHnDs and blank PFHnDs, i.e., PFHnDs synthesized as described above without 
dye. The blank PFHnD spectrum was then subtracted from the IR-1048 PFHnD spectrum. 




3.2.2 In vivo laser-activated PFHnD induced blood brain barrier opening 
All animal studies were conducted under the protocol approved by the Institutional 
Animal Care and Use Committee at Georgia Institute of Technology. Animal studies were 
performed as described previously [84]. Briefly, an injection of sustained released 
buprenorphine (IP, 0.8 mg/kg) was administered to each animal (Balb/c mouse, Jax), prior 
to anesthesia. Mice were anesthetized using a combination of isoflurane (2%, Henry 
Schein) and medical air (0.6 L/min, Airgas). Mice were positioned in a stereotax in the 
prone position, on a heating pad (Stoelting Co). Hair from the scalp was removed through 
shaving and depilatory cream. Proparacaine (0.5%, Henry Schein) was applied to the eyes, 
and a retro-orbital injection of 50 µL of 3% w/v sterile filtered Evans Blue (EB) (Sigma 
Aldrich) was administered with a co-injection of 70 µL of IR-1048 PFHnDs 
(~108 droplets). To allow for irradiation of the right side of the brain, animals were 
positioned underneath an unfocused 1.5 mm core diameter optical fiber (0.39 NA, 
Thorlabs, Inc.). Irradiation was performed with a Vibrant laser (10 Hz, 5-7 ns pulse length, 
Opotek Inc.) at a wavelength of 1064 nm (Figure 2).  
Six animal groups (n = 3 mice) were treated with a varying number of laser pulses 
and varying laser fluences. Three animal groups were exposed to a fluence of 56 mJ/cm², 
with the number of laser pulses being 300, 600, or 1200 pulses. As the PRF of the laser 
used was 10 Hz, the total laser irradiation time for these three groups was 30, 60, and 120 
seconds, respectively. Two additional animal groups were exposed to 600 laser pulses and 
had laser fluences of 38 or 70 mJ/cm². The sixth group of animals acted as a control group, 
with no laser irradiation or a co-injection. Other controls of co-injection without laser 
irradiation or laser irradiation without co-injection have been performed previously and 
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showed no BBB opening effect, so the control here serves a baseline for the experimental 
groups [84]. After laser irradiation, mice were allowed to recover, with no gross behavioral 
damage observed. After four hours, animals were euthanized via an IP Euthatal injection 
(150 mg/kg) followed by perfusion with 1X PBS (pH 6.8) and 4% paraformaldehyde 
(PFA). Heads were removed and post-fixed overnight in 4% PFA solution. After 24 hours, 
brains were excised, and whole brain photographs were taken. 
3.2.3 Ex vivo ultrasound and photoacoustic imaging 
Brains, excised and fixed, were placed on top of an 8% gelatin base in a container 
filled with degassed water. Samples were imaged using an ultrasound and photoacoustic 
(US/PA) imaging system (Vevo LAZR, FUJIFILM VisualSonics Inc.) with a 40 MHz 
ultrasound and photoacoustic imaging probe (LZ-550, FUJIFILM VisualSonics Inc.). The 
US/PA imaging system’s tunable Nd:YAG laser (20 Hz, 5-7 ns pulse length) was operated 
at a wavelength of 1064 nm and a fluence of  12-14 mJ/cm². Brains were imaged at an 
US/PA frame rate of 5 frames per second. Coronal and sagittal 3D US/PA images were 
collected with a distance step size of 0.102 mm for a total of about 14 mm and 12 mm, 
respectively. US/PA imaging was performed for all six animal groups.  
3.2.4 Ultrasound and photoacoustic image processing 
Coronal ultrasound and photoacoustic image sets were processed in MATLAB 
(Mathworks, Inc.). US/PA images were thresholded to reduce noise and exported to 
generate 3D whole brain images using AMIRA (Thermo Scientific). Top view and corner 
cut images of the treated (right) side of the brain, viewed from behind the cerebellum, were 
captured using AMIRA. 
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To determine the photoacoustic volume from IR-1048 dye for each brain, the 
photoacoustic data set for each coronal image was co-registered with its respective 
ultrasound data set, and any PA signal located outside of the co-registered US coronal 
section was removed. The treated (right side) PA signal area of each coronal section was 
determined based on the location of the PA signal within the image. Outliers from the 
location data set were removed as to eliminate any PA signal from the untreated (left) side 
of the brain that could have resulted from other sources, such as deoxygenated hemoglobin 
remaining within the vasculature post-perfusion. The area of PA signal was calculated by 
multiplying the total width and depth of the PA location data set in the image. After the 
area was calculated for each coronal image, volume was calculated by totaling the PA area 
for each brain and multiplying by the coronal image step size of 0.102 mm. 
3.2.5 Histology and immunohistochemistry  
After 3D US/PA imaging, brains were transferred to a solution of 30% sucrose and 
stored at 4ºC for five days. Brains were snap frozen, and 20 µm coronal sections were cut 
using a cryostat (Leica CM 1860, Leica Biosystems). For each brain, 48-60 sections were 
cut and analyzed, spanning a total region of 0.96-1.2 mm within the brain. Standard 
hematoxylin (Gill No. 2, Sigma-Aldrich) and eosin (VWR) (H&E) was performed. H&E 
pictomicrographs were captured using the bright field mode of a Zeiss AxioObserver Z1 
Microscope. Immunohistochemistry (IHC) was also performed using a secondary antibody 
of goat anti-mouse immunoglobulin G (IgG, H+L) tagged with Alexa Fluor 488 
(Invitrogen) and 4',6-diamidino-2-phenylindole (DAPI, Invitrogen). IHC pictomicrographs 
were captured with a Zeiss Laser Scanning Confocal Microscope 700.  
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Zen lite software (Zeiss) was used to evaluate the fluorescence area of the IHC 
pictomicrographs of each animal. Fluorescence area was calculated using the profile view 
in the Zen lite software. Using a rectangular profile, IgG fluorescence signal was displayed 
across each coronal slice and thresholded to remove background noise. The area of IgG 
fluorescence was then calculated based on the location of above-threshold fluorescence.   
3.3 Results 
3.3.1 IR-1048 laser-activated PFHnD characterization 
Lipid shelled, IR-1048 perfluorohexane nanodroplets (PFHnDs) were characterized 
by size, charge, and UV-VIS-NIR absorbance as shown below (Figure 8). PFHnDs had an 
average diameter of 265 ± 64.7 nm and a charge of -5.2 ± 4.4 mV in PBS (pH 7.4) (Figure 
8A-B). When activated, PFHnDs are expected to expand to 1.25 µm (5X their nanodroplet 
diameter), putting theses activated droplets in the size range of microbubbles used for FUS 
BBB opening [72, 97]. The optical absorbance spectrum measured for IR-1048 PFHnDs 
shows a peak optical absorption near 1064 nm, the wavelength used for laser-activation of 
PFHnDs (Figure 8C). Irradiation at 1064 nm allows for increased light penetration in tissue, 
enabling activation of PFHnDs at increased depths [75, 111]. Evans Blue (EB), the dye co-
administered with PFHnDs in in vivo experiments to qualitatively and macroscopically 
evaluate BBB opening, has a peak optical absorption near 600 nm and minimal absorption 
at 1064 nm. As a result, EB will not interact with the 1064 nm laser light used for laser-
activated PFHnD BBB opening and ex vivo imaging.  
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Figure 8. Characterization of IR-1048 perfluorohexane nanodroplets (PFHnDs). (A) IR-
1048 PFHnD size distribution, 265 ± 64.7 nm. (B) Zeta potential of IR-1048 PFHnDs, -5.2 
± 4.4 mV. (C) Normalized absorbance spectrum of IR-1048 PFHnDs with a peak optical 
absorption near 1064 nm and Evans Blue dye with a peak optical absorption near 600 nm. 
Image to the right shows appearance of IR-1048 PFHnDs, and Evans Blue can be seen in 
Figure 4. Both IR-1048 PFHnDs and Evans Blue are used for in vivo blood brain barrier 
opening experiments. 
3.3.2 Evans Blue extravasation and histological analysis of blood brain barrier opening 
induced by laser-activated PFHnDs 
Evans Blue extravasation and hematoxylin and eosin (H&E) staining was compared 
for each animal group based on the number of laser pulses used (Figure 9). EB 
extravasation provides a macroscopic view of BBB opening, and H&E staining evaluates 
the tissue for damage, with red blood cells (RBCs) in the tissue indicating 
microhemorrhages [25]. For 0 laser pulses, i.e., no laser irradiation, no EB extravasation 
was visible nor were there any abnormalities in the stained tissue (Figure 9A). At 300 laser 
pulses, EB extravasation is visible in the top-view photograph and coronal cross-section 
photograph, as indicated by the white, dashed oval, outlining the EB extravasation area 
(Figure 9B). H&E staining shows no differences between the treated (right) and untreated 
(left) sides of the brain (Figure 9B). When 600 laser pulses are used, EB extravasation is 
evident, and H&E staining shows some RBC extravasation, denoted by the bright red 
staining in the tissue slice (Figure 9C). With 1200 laser pulses, EB extravasation is also 
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apparent in both the top view and coronal cross-section images (Figure 9D). However, in 
this group, RBC extravasation was not found, and both treated (right) and untreated (left) 
tissue were the same (Figure 9D). As the number of laser pulses increases from 300 to 600, 
there is an increase in EB extravasation in both the top view and coronal cross-section 
photographs (Figure 9B-C). From 600 to 1200 laser pulses, there appears to be a similar 
EB extravasation footprint from the top view photographs, however, there is an increase in 
the area of EB extravasation in the coronal cross-section images from 600 to 1200 laser 







Figure 9. Representative Evans Blue (EB) dye extravasation top view and cross-sectional 
photographs and hematoxylin & eosin (H&E) pictomicrographs for varying number of 
laser pulses.  EB dye extravasation is outlined on the coronal cross-section with a white, 
dashed oval. H&E pictomicrographs are shown for both treated (right) and untreated (left) 
sides of the brain, with presence of red blood cells indicated by a white arrow and bright 
red staining within the tissue. Number of laser pulses includes (A) 0 laser pulses, (B) 300 
laser pulses, (C) 600 laser pulses, and (D) 1200 laser pulses. Note: Laser pulse Figure 9A 
and Figure 9C use the same images as laser fluence Figure 10A and Figure 10C, and 
experiments shown in (B-D) were performed at a laser fluence of 56 mJ/cm². Reprinted 
from [112]. 
Varying laser fluences were also evaluated for their effect on EB extravasation and 
H&E staining (Figure 10). As shown with 0 laser pulses, a fluence of 0 mJ/cm² (no laser 
irradiation) shows no EB extravasation or tissue abnormalities (Figure 9A, Figure 10A). 
When the laser fluence is increased to 38 mJ/cm², EB extravasation is evident in both the 
top view photograph and coronal cross-section photograph, where the EB extravasation of 
the coronal cross-section is outlined by a white, dashed oval (Figure 10B). H&E staining 
shows no differences between the treated and untreated sides of the brain (Figure 10B). In 
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the case of 56 mJ/cm², EB extravasation is widespread on the treated side of the brain, and 
RBC extravasation on the treated side is seen in H&E staining (Figure 9C, Figure 10C). At 
70 mJ/cm², EB extravasation occurs, and the treated side of the brain shows RBC 
extravasation (Figure 10D). By increasing laser fluence, EB extravasation spread increases, 
and at higher fluences, RBC extravasation is present (Figure 10B-D). 
 
Figure 10. Representative Evans Blue (EB) dye extravasation top view and cross-sectional 
photographs and hematoxylin & eosin (H&E) pictomicrographs for varying laser fluences.  
EB dye extravasation is outlined on the coronal cross-section with a white, dashed oval. 
H&E pictomicrographs are shown for both treated (right) and untreated (left) sides of the 
brain, with presence of red blood cells indicated by a white arrow and bright red staining 
within the tissue. Laser fluences include (A) 0 mJ/cm², (B) 38 mJ/cm², (C) 56 mJ/cm², and 
(D) 70 mJ/cm². Note: Laser fluence Figure 10A and Figure 10C use the same images as 
laser pulse Figure 9A and Figure 9C, and experiments shown in (B-D) were performed 
with 600 laser pulses. Reprinted from [112]. 
In addition to H&E staining, immunohistochemistry was performed to examine the 
extravasation of the secondary antibody mouse immunoglobulin G (IgG). Mouse IgG has 
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a molecular weight of 150 kDa and will not extravasate unless the BBB is opened, as the 
molecular weight limit for the BBB is 500 Da [9, 113]. As can be seen with the whole 
brain, coronal section and magnified confocal pictomicrographs of the 0 laser pulses/ 0 
mJ/cm² (no laser) case, fluorescence from DAPI is present, but there is minimal 
fluorescence signal from IgG (Figure 11A-B). Minimal fluorescence from IgG is seen in 
the untreated (left) side of the brain for all laser pulse and laser fluence variations (Figure 
11A, C, E, G, I, K). In the animal groups where irradiation occurs, IgG fluorescence is 
visible throughout the treated (right side) region (Figure 11D, F, H, J, L). When the number 
of laser pulses is varied, fluorescent intensity from 0 laser pulses to 600 laser pulses 
increases (Figure 11B, F, H), but from 600 to 1200 laser pulses, the fluorescence signal 
does not seem to change (Figure 11H, J). A similar trend is observed for increasing laser 
fluence where fluorescence increases on the treated side from 0 mJ/cm² to 56 mJ/cm² and 
remains constant from 56 to 70 mJ/cm² (Figure 11B, D, H, L). 
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Figure 11. Immunohistochemistry staining for secondary antibody IgG and DAPI. The 
coronal sections displayed are representative images of overall IgG (green) and DAPI 
(blue) fluorescence while the magnified images display the difference in IgG fluorescence 
between the untreated (left) and treated (right) sides. Magnified images are labeled as 
number of laser pulses/laser fluence (mJ/cm²). Reprinted from [112]. 
3.3.3 Ultrasound and photoacoustic analysis of IR-1048 dye extravasation 
Ex vivo ultrasound and photoacoustic (US/PA) imaging was performed, and 3D 
whole brain images were reconstructed to evaluate the volume of extravasated IR-1048 
dye. This NIR absorbing dye is contained within the PFHnDs; however, when laser-
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activated PFHnD BBB opening occurs, dye is able to extravasate across the BBB and 
produces a PA signal when imaged at its peak wavelength [84]. Reconstructed 3D US 
images are displayed in grayscale, and the reconstructed 3D PA signal is displayed using a 
hot colormap (Figure 12). At 0 pulses (no laser), there is minimal background PA signal 
present, but as the number of laser pulses increases from 300 to 1200 pulses, the volume 
of PA signal within the brain can be seen to increase in the treated (right side) of the brain. 
 
Figure 12. Reconstructed 3D top view and right side, corner cut images of ultrasound (US, 
grayscale) and photoacoustic (PA, hot colormap) data for varying number of laser pulses: 
(A) 0 pulses, (B) 300 pulses, (C) 600 pulses, and (D) 1200 pulses. Note: Laser pulse Figure 
12A and Figure 12C use the same images as laser fluence Figure 13A and Figure 13C, and 
experiments shown in (B-D) were performed with a laser fluence of 56 mJ/cm². Reprinted 
from [112]. 
The trend in PA signal volume can also be examined as laser fluence is varied 
(Figure 13). At 0 mJ/cm² (no laser), there is minimal signal, and as laser energy increases 
from 38 mJ/cm² to 70 mJ/cm², the PA signal volume increases. Although the volume of 
PA signal at 70 mJ/cm² is increased, the overall PA signal intensity appears to be lower 
than the intensity at 56 mJ/cm² (Figure 13C-D). 
 51 
 
Figure 13. Reconstructed 3D top view and right side, corner cut images of ultrasound (US, 
grayscale) and photoacoustic (PA, hot colormap) data for varying laser fluences: 
 (A) 0 mJ/cm², (B) 38 mJ/cm², (C) 56 mJ/cm², and (D) 70 mJ/cm². Note: Laser fluence 
Figure 13A and Figure 13C use the same images as laser pulse Figure 12A and Figure 12C, 
and experiments shown in (B-D) were performed with 600 laser pulses. Reprinted from 
[112]. 
3.3.4 Quantitative fluorescence and photoacoustic analysis 
Quantitative analysis of fluorescence signal from IgG and PA signal from IR-1048 
dye was completed for the five animal groups where laser irradiation was performed 
(Figure 14). The fluorescence area and PA volume were not calculated for the no laser (0 
laser pulses, 0 mJ/cm²) case, as there is no calculable fluorescence area or PA volume for 
this animal group. Examining the number of laser pulses from 300 to 600 pulses, there is 
an increase in fluorescence area (Figure 14A). However, fluorescence area measurements 
from 600 to 1200 pulses are similar in mean and median, potentially indicating a saturation 
point with regards to the area over which IgG is delivered to the tissue as the number of 
laser pulses increases. When the laser fluence is increased, the fluorescence area also 
increases (Figure 14B). With PA volume measurements, similar trends are seen (Figure 
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14C-D). There is an increase in PA volume as the number laser pulses increases from 300 
to 600 pulses, but there is not an increase when comparing 600 to 1200 laser pulses. As the 
laser fluence is increased from 38 mJ/cm² to 56 mJ/cm² to 70 mJ/cm², the PA volume 
increases.  
 
Figure 14. Quantitative evaluation of fluorescence area and photoacoustic volume for the 
varying number of laser pulses and laser fluences used. (A) Fluorescence area vs. number 
of laser pulses for 300, 600, and 1200 pulses. (B) Fluorescence area vs. fluence for 38, 56, 
and 70 mJ/cm². (C) Photoacoustic volume vs. number of laser pulses for 300, 600, and 
1200 laser pulses. (D) Photoacoustic volume vs. fluence for 38, 56, and 70 mJ/cm². The 
circle marker indicates the mean value calculated for each animal group. The horizontal 
line identifies the median, and the vertical line marked with crossbars identifies the 95% 





Through the variation of a range of laser fluences and laser pulses, the extent of 
laser-activated perfluorohexane nanodroplet (PFHnD) induced blood brain barrier (BBB) 
opening was controlled. BBB opening was evaluated through Evans Blue (EB) staining of 
the tissue, fluorescence produced by the secondary antibody IgG, and photoacoustic (PA) 
signal produced by IR-1048 dye. Damage to the tissue indicated by RBC extravasation was 
also evaluated to determine which range of laser fluences and laser pulses was safe (Figure 
9 - Figure 10). Overall, it was seen that the extent of BBB opening increased with increased 
laser fluence (Figure 14B, D). When the number of laser pulses was increased from 300 to 
600 pulses, there was an increase in fluorescence area and PA volume (Figure 14A, C). 
However, the trend in BBB opening remained constant when the number of laser pulses 
was increased from 600 to 1200. The results of these studies show how BBB opening can 
be modulated through the choice of laser parameters used for activation of PFHnDs. 
The increased extent of BBB opening for increased laser fluence used is expected. 
Due to the optical properties of tissue, the ability of light to penetrate tissue and vaporize 
the droplets is in part dependent on the amount of laser fluence used [111]. Therefore, an 
increased laser fluence used in laser-activated PFHnD induced BBB opening can result in 
increased depth penetration, and this increased fluence will likely activate more PFHnDs, 
causing BBB opening in a larger volume within the tissue. This tissue-fluence interaction 
may also explain the trend seen when the number of laser pulses is increased. Although an 
increased number of pulses will allow for an increased number of PFHnD droplet phase 
changes or oscillations, which may help to increase BBB opening, the laser fluence 
footprint is expected to be the same when the same fluence is used. As a result, there is 
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likely to be a limit to the extent of BBB opening when the same fluence is used but the 
number of laser pulses is increased.  
Furthermore, it is important to note that there were some cases where red blood cell 
extravasation occurred. When 56 mJ/cm² and 600 laser pulses were used, RBC 
extravasation was apparent in the tissue (Figure 9C, Figure 10C). In addition, at 70 mJ/cm² 
and 600 laser pulses, RBC extravasation was visible (Figure 10D). Thus, choosing lower 
fluences may be optimal to enable effective BBB opening without damage to the tissue. 
Interestingly, at 1200 laser pulses and a fluence of 56 mJ/cm², RBC extravasation was not 
seen (Figure 9D). There are a few possibilities as to why 1200 pulses did not show damage, 
such as variation per animal or slight differences in the PFCnD size distribution synthesized 
for each set of experiments. However, the trends seen in Evans Blue extravasation, IgG 
fluorescence, and IR-1048 dye delivery show that these slight differences have not affected 
the outcome of BBB opening, suggesting that damage should be seen in the 1200 laser 
pulse group (Figure 9D, Figure 11I, J, Figure 12D). As a result, the upper limit or guideline 
for safe, laser-activated PFHnD induced BBB opening, given these experiments, should be 
the lowest laser fluence and laser pulse number to show RBC extravasation, which is 56 
mJ/cm² and 600 laser pulses. 
Other parameters can also be explored to optimize laser-activated PFCnD induced 
BBB opening. With regard to laser parameters, the laser pulse repetition frequency (PRF) 
could be modified. In these studies, a laser PRF of 10 Hz was used. A lower PRF would 
increase the time between phase change events, potentially reducing the concentration of 
phase-changing PFHnDs within the laser irradiated volume which may help to reduce 
tissue damage seen at higher fluences. Laser irradiation wavelength could also be adjusted. 
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The current wavelength of 1064 nm used was selected for increased depth penetration into 
tissue, but other NIR absorbing wavelengths could be used. Regardless, effectiveness and 
extent of BBB opening would be dependent upon the peak absorption wavelength of the 
optical trigger within PFCnDs, so wavelength used should coincide with the optical trigger. 
PFCnD parameters would also affect BBB opening [96, 100], similar to how microbubbles 
affect BBB opening [19, 21, 22, 26]. Parameters such as PFCnD size, concentration, 
perfluorocarbon core, and encapsulated optical trigger can also affect the safety and 
efficacy of laser-activated PFHnD induced BBB opening. Overall, these studies focused 
on laser fluence and laser pulses used and provide a guideline to how PFCnD BBB opening 
can be controlled through laser irradiation. Nevertheless, there is still space to improve 
upon laser-activated PFCnD BBB opening, primarily through exploration of PFCnD 
parameters.  
A fully optimized laser-activated PFCnD induced BBB opening would allow laser-
activated PFCnDs to act in multiple roles in the monitoring and treatment of neurological 
diseases. US/PA imaging of extravasated photoacoustic contrast in the brain in vivo has 
been established [81, 114], and therefore PFCnDs could contribute to not only BBB 
opening but also US/PA contrast within the brain. Contrast provided via laser-activated 
PFCnDs could enable monitoring of BBB opening as well as monitoring of the delivery of 
any cargo, therapeutic or diagnostic, contained within PFCnDs. In addition, laser-activated 
PFCnD induced BBB opening would allow for delivery of other PA contrast agents, 
possibly furthering the capabilities of longitudinal or multiplexed US/PA imaging within 
the brain. Altogether, laser-activated PFCnD induced BBB opening and the versatility of 
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PFCnDs have the potential to play a significant role in US/PA imaging and therapy in the 
central nervous system. 
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CHAPTER 4. IN VITRO EXAMINATION OF PHOTOACOUSTIC 
CONTRAST AGENTS FOR ULTRASOUND AND 
PHOTOACOUSTIC IMAGING OF THE BRAIN 
4.1 Introduction 
Photoacoustic (PA) imaging relies on the optical absorption properties of the target 
being imaged [57, 115]. In the case of biomedical imaging, PA contrast can be produced 
via endogenous absorbers such as hemoglobin and melanin or from exogenous contrast 
agents such as optically absorbing dyes or metal nanoparticles [50, 51, 53]. In the last 
decade, PA imaging of the brain has emerged as a neuroscience tool that has relied on both 
endogenous and exogenous contrast imaging [58-62]. However, PA neuroimaging has 
often been limited to the vasculature or leaky tumors with limited studies being performed 
for extravascular contrast agent delivery [63-65, 116, 117]. As a result, there is a need to 
explore extravascular PA contrast delivery in the brain.  
Recently, tools for focused ultrasound (FUS) blood brain barrier (BBB) opening 
and in vivo ultrasound and photoacoustic (US/PA) imaging of delivered PA contrast with 
gold nanorods (AuNRs) have been developed [81]. Although delivery and imaging were 
successful, there were some limitations with respect to the PA contrast agent employed, 
i.e., AuNRs. Specifically, AuNRs are required to be delivered in high concentrations for 
sufficient PA imaging. These particles are neither biodegradable nor sufficiently cleared 
which brings concerns with regard to cytotoxicity and safety [118]. Furthermore, due to 
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their synthesized shape, AuNRs are prone to melting upon repeated pulsed laser irradiation 
which alters their absorption spectrum and limits their repeated or long term use [86].  
Another solid nanoparticle more promising for use as a PA imaging contrast in the 
brain is the copper sulfide nanoparticle (CuS NP). CuS NPs are photothermally stable, 
inorganic, semi-conductor nanoparticles that optically absorb in the second optical imaging 
window, near 1064 nm [119, 120]. CuS NPs are non-cytotoxic, biodegradable, and are 
cleared in a reasonable time frame [121]. As a nanoparticle providing stable PA contrast, 
CuS NPs appear promising for extravascular brain imaging.  
In addition to dyes or metallic nanoparticles, which produce a stable PA signal 
when imaged, dynamic nanoparticles, or phase change nanoparticles, can also be utilized 
for extravascular imaging in the brain. In particular, the phase change behavior of PFCnDs 
can not only be used to induce BBB opening but can also be used to provide dual US/PA 
imaging contrast [30, 74, 80, 82, 85, 86, 90]. Two subsets of laser-activated PFCnDs are 
of particular interest for use as dynamic US/PA contrast agents. Perfluoropentane 
nanodroplets (PFPnDs) with a bulk boiling point near physiological temperature (29ºC) 
produce a permanent, single phase change event from liquid droplet to stable gas bubble 
upon pulsed laser irradiation [83]. The behavior of laser-activated PFPnDs can be imaged 
over the course of seconds to provide information about the location of droplets in the 
imaging plane with respect to the background [30, 82]. PA signal of PFPnDs is highest in 
the first seconds, followed by a steady decline in signal [30, 82]. On the other hand, US 
signal is lowest in the first seconds, followed by a steady increase in signal and 
corresponding saturation of signal due to the vaporization of all PFPnDs in the imaging 
plane [30, 82]. Perfluorohexane nanodroplets (PFHnDs), with a bulk boiling point above 
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physiological temperature (57ºC) are also of interest for US/PA imaging in the brain, as 
they provide dynamic US contrast that can be localized through the use of different imaging 
algorithms due to their ability to repeatedly phase change [74, 91]. Through the use of 
laser-activated PFCnDs, dual US/PA image contrast is available, a benefit over agents that 
provide only PA or US image contrast.  
To examine the behavior of PA image contrast agents longitudinally, in vitro 
studies can be used to evaluate PA contrast agents in a high throughput manner [122-125]. 
Incubating nanoparticles with cells followed by US/PA imaging can provide information 
regarding the interaction of specific nanoparticles and cells. To evaluate PA contrast in the 
brain with in vitro studies, microglial cell lines are of interest. Microglial cells are the innate 
immune cells within the brain and act similarly to macrophages and lymphocytes in other 
parts of the body to protect the brain from disease and injury [126-128]. They comprise 
12% of the brain and remain predominantly in a resting state unless activated by the 
surrounding microenvironment [126]. As a result, microglia are likely to be first responders 
when interacting with foreign materials, such as nanoparticles for PA imaging [126, 128].  
One particular microglial cell line that is ideal for yielding a large number of cells quickly, 
enabling an extensive evaluation of PA contrast agents, is the BV-2 cell line, which 
originates from murine microglia [127, 129]. BV-2 cells have been evaluated as an 
appropriate alternative to primary microglia cultures [127, 129] and act as a suitable cell 
culture model for studying extravascular PA contrast in vitro. 
In the studies outlined below, two nanoparticle types are incubated with BV-2 cells.  
CuS NPs provide stable photoacoustic contrast, and laser-activated PFPnDs are evaluated 
with their dynamic, dual US/PA imaging contrast. These two PA contrast agents are 
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examined at different time points to determine which particles are ideal for US/PA imaging 
in the brain.  
4.2 Materials and methods 
4.2.1 Synthesis and characterization of copper sulfide nanoparticles (CuS NPs) 
Copper sulfide nanoparticles (CuS NPs) were synthesized as described previously 
[130], followed by silica and poly-L-lysine (PLL) coating. Prior to all reactions, glassware 
was rinsed with nanopure water and cleaned with aqua regia. Into 250 mL of nanopure 
water, one mmol of Copper(II) chloride (Sigma-Aldrich) was added followed by 0.68 
mmol of sodium citrate (Sigma-Aldrich). One molar sodium sulfide (Sigma-Aldrich) was 
then added to the solution, turning it from a blue to brown color. The reaction was allowed 
to stir for 5 minutes at room temperature and was then moved to a 90 ºC water bath and 
stirred at 900 rpm for 15 minutes, with the solution turning a hunter green color. After 15 
minutes, the solution was transferred to an ice-cold water bath to cool. Cooling of the CuS 
NP solution was followed by pegylation of CuS NPs with a 1:1 ratio of PEG-SH (5 kDa, 
Laysan Bio). CuS NPs and PEG-SH were left to mix overnight. 
After mixing, pegylated CuS NPs were washed via centrifugation. Silica coating 
was then performed by mixing 2 mL of optical density (OD) 15 CuS NPs with 3 mL of 
isopropyl alcohol (IPA) in a 20 mL scintillation vial at 400 rpm. A 1.2 mL, 3% solution of 
tetraethyl orthosilicate (Sigma-Aldrich) in IPA was added to the vial followed by 1.2 mL 
of ammonium hydroxide (VWR). The reaction was allowed to stir for 2 hours. The 
resulting solution was washed twice at 500 rcf for 15 minutes before being resuspended in 
4 mL of nanopure water and sent through a 0.20 µm sterile filter.  
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Silica coated CuS NPs were then prepared for PLL coating by diluting them to ~2 
OD. Following dilution, 0.833 mM PLL (Sigma-Aldrich) was added per milliliter of CuS 
NPs. The solution was sonicated for one minute and left at room temperature for two hours. 
PLL coated CuS NPs were then washed twice via centrifugation at 500 rcf for 5 minutes. 
CuS NPs were then resuspended in PBS and stored at 4ºC prior to cell studies.  
CuS NP size and zeta potential were measured in PBS (pH 7.4) using a dynamic 
light scattering instrument (Zetasizer Nano ZS, Malvern Instruments Ltd.). A 
spectrophotometer (Evolution 220, Thermo Scientific) was used to measure the absorbance 
of the CuS NPs. 
4.2.2 Synthesis and characterization of laser-activated 760 nm perfluoropentane 
nanodroplets (PFPnDs) 
Perfluoropentane nanodroplets (PFPnDs) were synthesized using a 760 nm 
absorbing dye (Epolight 9151, Epolin, Inc.), perfluoropentane (FluoroMed, L.P.), and a 
lipid shell comprised of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] (DSPE-PEG(2000), 25 mg/mL, Avanti Polar Lipids, 
Inc.) and 1,2-distearoyl-sn-glycero-3-phosphocholine (18:0 PC (DSPC), 25 mg/mL, 
Avanti Polar Lipids). To create the lipid shell, 40 µL of DSPE-PEG(2000) and 8 µL of 
18:0 PC (DSPC) were added to a 10 mL pear-shaped flask (Sigma-Aldrich). A 760 nm dye 
solution was prepared in chloroform (1 mg/mL), and 200 µL was added to the flask. An 
additional 1 mL of chloroform was added to the flask to enable a smooth lipid cake. A 
rotary evaporator (Rotovapor, Büchi) was used at reduced pressure to remove the 
chloroform from the flask leaving a 760 nm dye-coated lipid cake. The lipid cake was 
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resuspended in 1 mL of PBS using a water bath sonicator (VWR, 180W). The solution was 
placed in a 7 mL scintillation vial, and 150 µL of PFP was added. The vial was vortexed 
for 10 seconds (Vortex Mixer, Fisher Scientific) and sonicated for five minutes in an ice-
cold water bath (VWR, 180 W). The PFPnD solution was transferred to a 2 mL centrifuge 
tube and centrifuged for 60 seconds in a mini-centrifuge (Mini-Spin, Eppendorf) to remove 
excess PFP and 760 nm dye. The supernatant was transferred to a new 2 mL centrifuge 
tube, and the pellet was discarded. Prior to cell studies, 760 nm PFPnDs were stored at 4ºC. 
The PFPnD size and zeta potential were measured in PBS similarly to CuS NPs as 
mentioned in section 4.2.1. 760 nm dye in chloroform was also measured to characterize 
the absorbance spectrum (Evolution 220, Thermo Scientific) of the 760 nm PFPnDs. 
4.2.3 BV-2 cell culture and nanoparticle incubation 
BV-2 cells were cultured in a 1:1 Dulbecco’s Modified Eagle Medium and Ham’s 
F-12 (DMEM:F12) + L-glutamine media (VWR) supplemented with 5% heat-inactivated 
fetal bovine serum (FBS) and 1% penicillin-streptomycin. Heat-inactivation of FBS was 
performed by leaving FBS in 56ºC water for 30 minutes. Cells were passaged every 3 days 
using a cell scrapper at a subcultivation ratio of 1:20. For incubation with nanoparticles, 
cells were cultured to 60% confluence.  
CuS NPs and 760 nm PFPnDs were prepared in PBS for incubation with BV-2 
cells. All nanoparticles were sterilized via UV light for 30 minutes. Three cell groups were 
cultured for the US/PA imaging experiments – cells containing CuS NPs, cells containing 
760 nm PFPnDs, and control cells with no incubated nanoparticles. One mL of CuS NPs 
were incubated with BV-2 cells at an OD of 1.8 (~3 x 10¹³ nanoparticles/mL [130]) while 
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one mL of 760 nm PFPnDs were incubated with BV-2 cells at a ratio of 1:1000 from stock 
solution (~1010 nanoparticles/mL [84]). At cell and nanoparticle incubation time points of 
t = 4 hours and 24 hours, cells were fixed and prepared for ultrasound and photoacoustic 
imaging.  
4.2.4 Ultrasound and photoacoustic imaging of PA labeled BV-2 cells 
Ultrasound and photoacoustic imaging were performed using a tissue-mimicking 
gelatin inclusion phantom. Cell-containing gelatin inclusions were made by diluting cells 
1:1 in a 16% solution of gelatin such that 20 µL of the solution contained 2.5 x 104 cells. 
The cell-gelatin mixture was then pipetted onto an 8% gelatin base in a plastic container to 
form a dome-shaped cell inclusion (Figure 15). For the cell and nanoparticle incubation 
time point t = 4 hours, nanoparticle labeled cell inclusions of CuS NPS, 760 nm PFPnDs, 
and control cells without nanoparticles were prepared. For the incubation time point of t = 
24 hours, only nanoparticle containing cell inclusions were prepared.  
US/PA imaging at the two incubation time points was performed by filling the 
phantom container with degassed water. Phantom inclusions were imaged with a 
photoacoustic and ultrasound imaging system (Vevo LAZR, FUJIFILM VisualSonics Inc.) 
with a 40 MHz ultrasound and photoacoustic imaging probe (LZ-550, FUJIFILM 
VisualSonics Inc.). The system’s tunable ND:YAG laser (20 Hz, 5-7 ns pulse length) was 
operated at two wavelengths. US/PA imaging of the CuS NP labeled cells was performed 
at a wavelength of 1064 nm and at a fluence of 24 mJ/cm². US/PA imaging of the 760 nm 
PFPnD labeled cells was performed at a wavelength of 760 nm and at a fluence of 22 
mJ/cm². Imaging was performed at a US/PA frame rate of 5 frames per second. 
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Spectroscopic US/PA imaging was also performed for labeled cells at t = 4 hours. Each set 
of labeled cells was imaged at a range of wavelengths from λ = 680 nm to 970 nm at 
increments of 5 nm using the Vevo LAZR system described previously. Data acquired from 
US/PA imaging was exported and processed using MATLAB (Mathworks). Data was 
collected for multiple inclusions of each labeled cell group (n = 3 imaged gelatin inclusions 
per group).   
 
Figure 15. Depiction of ultrasound and photoacoustic (US/PA) imaging of labeled BV-2 
cells. Two types of nanoparticles were incubated with BV-2 cells for various time points, 
followed by US/PA imaging of the nanoparticle labeled cells.  
4.3 Results 
4.3.1 Characterization of dynamic and stable nanoparticles 
Prior to incubation with cells, the two nanoparticles were characterized by 
absorbance, size, and zeta potential (Figure 16). CuS NPs have peak absorbance near 1064 
nm, making 1064 nm a suitable wavelength for laser irradiation of these particles. PFPnDs 
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have a peak absorbance near 760 nm, making 760 nm a preferred wavelength for laser 
irradiation of the 760 nm PFPnDs (Figure 16A) . With respect to size, 760 nm PFPnDs had 
the largest diameter, at 342 nm. PLL, silica coated CuS NPs had a peak diameter of 164 
nm (Figure 16B). Zeta potential for the nanoparticles varied slightly, with the lipid-based 
nanoparticle being negatively charged (760 nm PFPnDs peak voltage = -10.3 mV) and the 
solid nanoparticle being positively charged (CuS NP peak voltage = 6.03 mV) (Figure 
16C). 
 
Figure 16. Characterization of copper sulfide nanoparticles (CuS NPs) and 760 nm 
perfluoropentane nanodroplets (760 nm PFPnDs). (A) Absorbance spectrum of CuS NPs 
having a peak absorption around 1064 nm and the 760 nm dye used in PFPnDs having a 
peak absorption near 760 nm. (B) Size distributions for the two nanoparticle types. (C) 
Zeta potential for the two nanoparticle types. 
4.3.2 Evaluation of the photoacoustic signal from dynamic and stable nanoparticles  
US/PA imaging of the BV-2, nanoparticle labeled cell inclusions allowed for 
evaluation of nanoparticle behavior at different time points. Specifically, PA signal, as 
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denoted by the hot colormap, evaluated for 760 nm PFPnDs over the nanoparticle 
incubation time points of t = 4 hours and 24 hours shows a decrease in signal as incubation 
time increases (Figure 17, Figure 18). On the other hand, the PA signal for CuS NPs from 
4 to 24 hours remains approximately constant. The control cells, imaged at laser irradiation 
wavelengths of 760 nm and 1064 nm, show minimal to no signal within the dome shaped 
gelatin inclusion. For the different nanoparticles incubated with cells, PA signal intensity 
does vary, with 760 nm PFPnDs producing the higher intensity PA signals qualitatively in 
comparison to CuS NPs (Figure 17).  
 
Figure 17. Ultrasound and photoacoustic imaging of BV-2 cells incubated with 760 nm 
perfluoropentane nanodroplets (PFPnDs) and copper sulfide nanoparticles (CuS NPs) and 
imaged at time points t = 4 and 24 hours. Cells were imaged at the peak wavelength of the 
incubated photoacoustic nanoparticle. i.e., 760 nm for 760 nm PFPnDs and 1064 nm for 
CuS NPs. Control cells (i.e., cells without photoacoustic nanoparticles) were imaged at 
both 760 nm and 1064 nm. 
Looking at PA signal quantitatively can also show the trends seen above in Figure 
17. Mean photoacoustic signal was calculated by averaging a PA region of interest (ROI) 
within the cell containing inclusion of the first image frame collected. This mean PA signal 
was  then averaged with the PA ROIs of the first image frame collected from two other cell 
 67 
containing inclusions of the same nanoparticle type. Thus, three cell inclusions were 
imaged for each nanoparticle group.  PA signal was also normalized for each nanoparticle 
group to highlight the trends in signal change from 4 hours to 24 hours. Due to the size of 
the data sets, photoacoustic signal and normalized photoacoustic signal was plotted, 
showing the mean, median, and 95% confidence interval for each nanoparticle labeled 
group (CuS NPs, 760 nm PFPnDs, and Control Cells) and time point (4 and 24 hours).   
Overall, average PA signal is the highest for the 760 nm PFPnDs incubated with 
BV-2 cells (Figure 18A). However, there is a decrease in the mean PA signal from t = 4 
hours to 24 hours for 760 nm PFPnDs, approximately a 30% decrease (Figure 18B). CuS 
NPs incubated with BV-2 cells produce a lower PA signal at both t = 4 hours and t = 24 
hours compared to 760 nm PFPnDs. However, from t = 4 hours to 24 hours, signal from 
CuS NPs is approximately constant (Figure 18). In comparison to t = 4 hours, the mean 
CuS NP PA signal increases at 24 hours. Control cells imaged at t = 4 hours at laser 
irradiation wavelengths of 760 nm and 1064 nm show minimal PA signal coming from 
control cells incubated without PA sensitive nanoparticles. 
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Figure 18. Photoacoustic (PA) signal for BV-2 cells incubated with 760 nm PFPnDs and 
CuS NPs and imaged at time points t = 4 and 24 hours. (A) PA signal is shown for each 
group of labeled cells, including both sets of control cells at t = 4 hours, and is described 
by the mean, median, and 95% confidence interval for each nanoparticle labeled cell group 
and time point. (B) Normalized PA signal is shown for each group of labeled cells and is 
described by the mean, median, and 95% confidence interval.  
Photoacoustic signal for each set of labeled cells was also examined 
spectroscopically at t = 4 hours. Each set of labeled cells was imaged at a range of 
wavelengths from λ = 680 nm to 970 nm at increments of 5 nm. PA spectroscopic imaging 
was performed to evaluate the behavior of the nanoparticles when incubated with cells and 
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how this signal compares to the nanoparticle signal measured using the UV-VIS 
spectrophotometer for optical absorption (Figure 16A). Overall, the captured PA 
spectroscopic signals trend similarly to the absorbance spectra measured with the UV-VIS 
spectrometer with a few exceptions. CuS NPs have a broad PA spectrum, with relatively 
high PA signals from 680 nm to 970 nm. This trend is similar to the absorbance spectrum; 
however, relative absorbance is lower at wavelengths of 680-800 nm. Also, in comparison 
to the absorbance spectrum, peak PA signal for CuS NPs is slightly red-shifted, with peak 
PA signal falling in the 900 nm range. For 760 nm PFPnDs, PA signal has the two-peak 
behavior seen with the 760 nm dye absorbance spectrum, with peaks near 700 nm and 760 
nm. However, both PA signal peaks from 760 nm PFPnDs are similar in relative PA signal 
in comparison to the absorbance spectra of 760 nm dye. The 760 nm PFPnDs show a sharp 
decrease in PA signal after 800 nm, also seen with the absorbance spectrum. Overall, 
examining both groups of nanoparticles labeled cells shows that each set of cells can be 
distinguished spectroscopically.   
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Figure 19. Spectroscopic photoacoustic signal for nanoparticle labeled cell inclusions at t 
= 4 hours. The CuS NP PA spectrum is shown in green squares while the 760 nm PFPnD 
spectrum is shown in blue circles.  
In addition to longitudinal evaluation of US/PA signal from nanoparticle labeled 
cell inclusions, US/PA signal can also be evaluated over a shorter period of time, i.e., 
seconds. PA signal and ultrasound difference signal for each nanoparticle labeled cell 
inclusion was plotted over 4 seconds (Figure 20). US difference signal (ΔUS) was 
calculated by subtracting the US signal of cell inclusions before US/PA imaging and laser 
irradiation from the US signal acquired during US/PA imaging. In the case of cells labeled 
with a stable nanoparticle, such as CuS NPs, there should be little difference in US signal 
before and during irradiation. However, with dynamic nanoparticles like 760 nm PFPnDs 
which produce US contrast with laser irradiation, US signal should change. Thus, 
calculating the ΔUS provides information regarding how the US signal changes while 
removing any US signal that arises from the background.  
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Over the 4 second time interval, control cells imaged at 760 nm and 1064 nm show 
minimal PA signal due to the lack of an incubated PA sensitive particle, and therefore PA 
signal acquired at these wavelengths for control cells is due to noise (Figure 20). ΔUS is 
also minimal and relatively unchanging over time as the control cells experience no 
dynamic behavior. For the CuS NP labeled cells, both ΔUS and PA signals are constant 
(Figure 20). PA signals at t = 4 hours and 24 hours are similar over the 4 second interval 
in both behavior and signal intensity. The same can be said for ΔUS for CuS NP labeled 
cells. The difference in US signal of the CuS NP labeled cells is minimal and consistent 
over time. As a result, in an imaging session, CuS NPs produce stable PA contrast and no 
US contrast and continue to behave this way regardless of the imaging time point, t = 4 or 
24 hours.    
The PA and ΔUS signal of 760 nm PFPnD labeled cells show dynamic trends over 
time. PA signal for cells labeled with 760 nm PFPnDs steadily decreases over time, after 
an initial peak PA signal. This initial peak PA signal occurs with the first few laser pulses 
in PA imaging and results from the single phase change behavior of the PFPnDs. After 
PFPnDs in the imaging plane phase change, the PA signal appears lower and constant and 
is the result of the nanoparticle’s photoabsorber producing PA signal [30, 75]. In addition, 
the PA signal produced at t = 4 hours is higher than the signal produced at t = 24 hours. 
ΔUS for 760 nm PFPnDs increases as time increases due to the phase change of these 
particles from liquid to gas, resulting in an echogenic US signal [30, 75]. Over time, the 
US signal begins to saturate due to laser irradiation of all of the particles in the imaging 
plane [30]. The ΔUS of 760 nm PFPnD labeled cells reduces at t = 24 hours in comparison 
to t = 4 hours. However, both time points show an initial ΔUS increase from 0 to 1 seconds, 
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followed by the signal saturating to a steady state. As a result, these nanoparticles continue 
to display characteristic dynamic US/PA behavior regardless of imaging time point.    
 
Figure 20. Photoacoustic and ultrasound difference signal (ΔUS) for each group of labeled 
BV-2 cells at t = 4 hours and 24 hours and for control cell groups imaged at 760 nm and 
1064 nm for t = 4 hours. (A) PA signal tracked over 4 seconds of US/PA imaging. (B) ΔUS 
signal tracked over 4 seconds of US/PA imaging.   
4.4 Discussion 
By analyzing the interaction of different PA nanoparticles with BV-2 cells, an 
understanding of how these nanoparticles may react in vivo can be gained. Overall, CuS 
NPs maintained PA signal over time, with a slight increase in mean PA signal from t = 4 
hours to t = 24 hours (Figure 18). The 760 nm PFPnDs produced the highest PA signal 
values, however, mean PA signal from t = 4 hours to t = 24 hours decreased. Furthermore, 
the behavior of nanoparticle labeled BV-2 cells was also evaluated over the course of 
seconds within the individual imaging session (Figure 20). CuS NPs showed no changes 
in PA or ΔUS signal when imaged over this short time scale. On the other hand, 760 nm 
PFPnDs showed dynamic behavior. That is, their PA and ΔUS signals showed identifiable 
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trends in signal change over time. Overall, the studies help to highlight the usefulness of 
each PA nanoparticle type for different imaging time scales.  
Copper sulfide nanoparticles appear to be most promising for long-term US/PA 
imaging studies. PA signal from CuS NPs over the 24 hour time point compared to that of 
760 nm PFPnDs remained steady, thus making them better potential candidates for imaging 
in situations where multi-day time points are used. Although there are advantages to using 
copper sulfide nanoparticles, there also appear to be a few disadvantages. For example, the 
PA contrast produced by CuS NPs was significantly reduced in comparison to that of 760 
nm PFPnDs. The total number of CuS NPs incubated with BV-2 cells was estimated to be 
near 3 x 10¹³ nanoparticles, while the number of droplets used was estimated to be 1 x 1010 
nanoparticles. The lower PA signal provided by CuS NPs suggests that an increase in 
concentration delivered to the cells would be required, creating some concern for future 
studies regarding nanoparticle overdose to obtain sufficient PA signal. Additionally, the 
synthesized CuS NPs used in these studies had a peak zeta potential that was positively 
charged, which may have affected the optimal uptake by BV-2 cells (Figure 16C). As 
phagocytic cells, like activated microglia, act preferentially with negatively charged 
particles, the positively charged CuS NPs uptake may have been reduced [131, 132]. As a 
result, CuS NPs appear to be favorable for long-term US/PA imaging studies of 
extravascularly delivered contrast agents but require further optimization prior to use.  
The characteristics of 760 nm PFPnDs appear to be most ideal as a short term 
extravascular imaging agent. Their dynamic phase change behavior provides sufficient 
US/PA imaging contrast, allowing for localization of 760 nm PFPnDs within the tissue. 
They are also triggered and imaged at 760 nm whereas PFHnDs used for BBB opening are 
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triggered at 1064 nm, reducing overlap between the PA signal used to evaluate 
extravasation (1064 nm) and the PA signal of the 760 nm PFPnDs. The 760 nm PFPnDs 
present a few limitations for longitudinal study but could also be optimized to improve 
their utility. The current peak diameter of 342 nm does reduce the number of PFPnDs 
capable of extravasating across the BBB. However, laser-activated PFHnD induced BBB 
opening has shown extravasation of micron sized red blood cells under certain conditions 
[84]. PFPnDs should be optimized for smaller diameters to improve extravasation of 
PFPnDs across the BBB when safe (i.e., without RBC extravasation) laser-activated 
PFHnD BBB opening is performed. In addition, improved loading of 760 nm PFPnDs with 
an increased concentration of 760 dye could improve longitudinal image contrast. Similar 
to the laser-activated PFHnDs used for BBB opening, PA sensitive dye is released when 
PFPnDs are vaporized, thus allowing the optically triggered dye to remain available for 
imaging after nanodroplet phase change. The 760 nm optically triggered dye could then be 
used for PA imaging contrast once the vaporized PFP gas bubble has diffused and is no 
longer detectable as US imaging contrast.  As a result, 760 nm PFPnDs provide advantages 
for short term (hours) in vivo US/PA imaging of extravascular contrast and have the 
potential to be optimized for longitudinal imaging purposes.  
  
 75 
CHAPTER 5. DELIVERY OF PHOTOACOUSTIC CONTRAST 
VIA LASER-ACTIVATED PERFLUOROCARBON 
NANODROPLET INDUCED BLOOD BRAIN BARRIER 
OPENING FOR IN VIVO IMAGING OF THE BRAIN 
5.1 Introduction  
Ultrasound (US) and photoacoustic (PA) imaging of the brain has made progress 
in recent years, however, both modalities still have limitations. US imaging has limitations 
with respect to the acoustic impedance mismatch between the ultrasound transducer and 
skull as well as due to the attenuation of ultrasound signal from the skull to the brain tissue 
[32]. In many cases, partial removal of the skull is required to achieve adequate US imaging 
[43]. PA neuroimaging has been able to overcome some of the limitations it shares with 
US imaging due to the photoacoustic effect and therefore the use of light to interrogate the 
brain [45, 46]. Unfortunately, a drawback of PA imaging is its limited depth penetration 
due to optical absorption and scattering of the tissue. Thus, achievements in PA 
neuroimaging are currently limited to the pre-clinical space [58-62].  
In pre-clinical imaging, combined US/PA imaging has the potential to be a 
resourceful neuroimaging tool. US/PA imaging is cost-effective, efficient, portable, and 
capable of noninvasive, whole brain imaging unlike other optically based imaging 
techniques [47, 67, 68]. As a result, US/PA imaging has the potential to monitor 
development of neurological diseases and disorders through functional molecular imaging 
of US/PA imaging contrast.  
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As US/PA imaging contrast agents, laser-activated perfluorocarbon nanodroplets 
(PFCnDs) provide dual contrast, making them advantageous over only PA or US contrast 
agents. For neuroimaging, where both US and PA imaging face challenges, laser-activated 
PFCnDs present themselves as a contrast agent resolvable by information provided by both 
imaging modalities. Incorporating laser-activated PFCnDs with bulk boiling points near or 
above physiological temperature, such as perfluoropentane (PFP) and perfluorohexane 
(PFH), enables uncomplicated US/PA signal analysis to easily localize PFCnD signal 
within the imaged target [30, 74, 82, 85, 91]. In particular, laser-activated PFPnDs can be 
monitored via their US and PA signals over short periods of time to distinguish their phase 
change event from liquid nanodroplet to stable gas bubble from the background [30, 82]. 
Laser-activated PFHnDs produce PA signal but are more characteristically defined by their 
repeated phase change behavior which results in a distinct ultrasound signal that enables 
super-resolution imaging [74, 85, 90, 91]. In addition, lipid shelled PFCnDs are 
biocompatible and can be functionalized with targeting moieties [82]. Consequently, 
PFCnDs present themselves as an attractive US/PA imaging tool in pre-clinical 
neuroimaging. 
Recently, a multiplexed system consisting of color-coded laser-activated 
perfluoropentane nanodroplets for US/PA imaging was developed [82].  PFPnDs were 
labled with different photoabsorbers of narrow bandwidth optical absorption spectra. This 
labeling allowed for subpopulations of PFPnDs to be tuned to specific laser wavelengths 
and therefore selectively phase changed. By employing the optical properties of the PFPnD 
subpopulations along with the algorithms developed to localize the PFPnDs based on their 
dynamic US/PA imaging signals, PFPnD subpopulations could be distinguished from one 
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another. Thus, this multiplexed system can be incorporated in a variety of applications 
through the functionalization of PFCnDs to target specific biomarkers of interest.      
The studies described in this chapter focus on in vivo US/PA neuroimaging. 
Delivery of the laser-activated PFHnD optical trigger, IR-1048 dye, is imaged at 1064 nm 
at various time points to monitor extravasation over time. In addition, utilizing the core 
characteristics of the previous multiplexed US/PA imaging studies, PFCnDs are 
incorporated in a multi-stage opening and delivery system. This demonstration is 
performed first by opening the BBB using laser-activated PFHnDs optically triggered at 
1064 nm (1064 nm PFHnDs) followed by an injection of PFPnDs optically triggered at 760 
nm (760 nm PFPnDs). PFPnDs for US/PA imaging can then be triggered at a given time 
point to allow for localization of PFPnD signal within the brain.  
5.2 Materials and methods 
5.2.1 Synthesis and characterization of perfluorocarbon nanodroplets (PFCnDs) 
IR-1048 PFHnDs (1064 nm PFHnDs) were synthesized as described previously in 
section 3.2.1. Synthesis of 760 nm PFPnDs was described in section 4.2.2. To characterize 
both nanodroplets, size and zeta potential were measured in PBS (pH 7.4) using a dynamic 
light scattering instrument (Zetasizer Nano ZS, Malvern Instruments Ltd.). A 
spectrophotometer (Evolution 220, Thermo Scientific) was used to measure the absorbance 
of the PFCnDs. To generate the absorbance spectrum of 1064 nm PFHnDs, a 
spectrophotometer was used to measure 1064 nm PFHnDs and blank PFHnDs, i.e., 
PFHnDs synthesized as described above without dye. The blank PFHnD spectrum was then 
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subtracted from the 1064 nm PFHnD spectrum. The same procedure was performed to 
generate the absorbance spectrum of 760 nm PFPnDs. 
5.2.2 Laser-activated PFHnD induced blood brain barrier opening  
All animal studies were conducted under the protocol approved by the Institutional 
Animal Care and Use Committee at Georgia Institute of Technology. Animal studies were 
performed as described previously [84, 112]. Briefly, an injection of sustained released 
buprenorphine (IP, 0.8 mg/kg) was administered to each animal (Balb/c mouse, Jax) prior 
to anesthesia. Mice were anesthetized using a combination of isoflurane (2%, Henry 
Schein) and medical air (0.6 L/min, Airgas). Mice were positioned in a stereotax in the 
prone position on a heating pad (Stoelting Co). Hair from the scalp was removed through 
shaving and depilatory cream. Proparacaine (0.5%, Henry Schein) was applied to the eyes, 
and a retro-orbital injection of 50 µL of 3% w/v sterile filtered Evans Blue (EB) (Sigma 
Aldrich) was administered with a co-injection of 70 µL of IR-1048 PFHnDs 
(~108 droplets). To allow for irradiation of the right side of the brain, animals were 
positioned underneath an unfocused 1.5 mm core diameter optical fiber (0.39 NA, 
Thorlabs, Inc.). Irradiation was performed with a Vibrant laser (10 Hz, 5-7 ns pulse length, 
Opotek Inc.) at a wavelength of 1064 nm (Figure 2). Animals (n = 5) were irradiated at a 
laser fluence of 38 mJ/cm² for 600 pulses (t = 60 seconds) as to prevent laser irradiation 
damage [112].  
5.2.3 In vivo imaging of extravasated 1064 nm dye 
In vivo imaging was performed twice, immediately after the blood brain barrier 
(BBB) opening procedure and four hours after, prior to animal euthanasia (Figure 21). 
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Animals were imaged using a photoacoustic and ultrasound imaging system (Vevo LAZR, 
FUJIFILM VisualSonics Inc., Figure 23) with a 21 MHz ultrasound and photoacoustic 
imaging probe (LZ-250, FUJIFILM VisualSonics Inc.). The system’s tunable Nd:YAG 
laser (20 Hz, 5-7 ns pulse length) was operated at a wavelength of 1064 nm and a laser 
fluence of 24 mJ/cm². Imaging was performed at a US/PA frame rate of 5 frames per 
second. Coronal 3D US/PA images were collected with a distance step size of 0.102 mm 
for a total of about 13 mm for both US/PA imaging time points. 
After the first in vivo imaging session, mice were allowed to recover, with no gross 
behavioral damage observed. After four hours, mice were imaged again followed by animal 
euthanasia via an IP Euthatal injection (150 mg/kg) and perfusion with 1X PBS (pH 6.8) 
and 4% paraformaldehyde (PFA). Heads were removed and post-fixed overnight in 4% 
PFA solution. After 24 hours, brains were excised, and ex vivo US/PA imaging was 
performed. 
 
Figure 21. Timeline of laser-activated PFHnD induced BBB opening and in vivo and ex 
vivo imaging sessions.  
5.2.4 In vivo imaging of 760 nm perfluoropentane nanodroplets 
Immediately after the laser-activated PFHnD induced BBB opening, mice under 
anesthesia were taken out of the stereotax and placed in the supine position (Figure 22). A 
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jugular injection of 75 µL 760 nm PFPnDs was administered and mice were allowed to 
recover, with no gross behavioral damage observed. After four hours, animals were 
anesthetized and imaged using using a photoacoustic and ultrasound imaging system (Vevo 
LAZR, FUJIFILM VisualSonics Inc., Figure 23) with a 21 MHz ultrasound and 
photoacoustic imaging probe (LZ-250, FUJIFILM VisualSonics Inc.) and a custom built 
fiber jacket used to increase the US/PA system’s laser focus depth from 9-11 mm to 11-13 
mm. The system’s tunable ND:YAG laser (20 Hz, 5-7 ns pulse length) was operated at two 
wavelengths. Animals were first imaged at 760 nm at a laser fluence of 22 mJ/cm² followed 
by imaging at 1064 nm and a laser fluence of 24 mJ/cm². Imaging was performed at a 
US/PA frame rate of 5 frames per second. Coronal 3D US/PA images at each wavelength 
were collected with a distance step size of 0.102 mm for a total of about 13 mm. 
After in vivo imaging, animals were euthanized via an IP Euthatal injection (150 
mg/kg) followed by perfusion with 1X PBS (pH 6.8) and 4% paraformaldehyde (PFA). 
Heads were removed and post-fixed overnight in 4% PFA solution. After 24 hours, brains 
were excised, and ex vivo US/PA imaging was performed. 
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Figure 22. Timeline of laser-activated PFHnD induced BBB opening and injection of 760 
nm PFPnDs, followed by in vivo and ex vivo imaging. 
 
Figure 23. In vivo imaging setup for brain imaging. For studies mentioned in section 5.2.3, 
in vivo imaging was performed without the laser fiber jacket as shown in the zoomed-in 
view of the transducer to the right. Studies conducted as described in section 5.2.4 utilize 
the fiber jacket as shown.  
5.2.5 Ex vivo ultrasound and photoacoustic imaging 
Brains, excised and fixed, were placed on top of an 8% gelatin base in a container 
filled with degassed water. Samples were imaged using an ultrasound and photoacoustic 
imaging system (Vevo LAZR, FUJIFILM VisualSonics Inc.) with a 40 MHz ultrasound 
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and photoacoustic imaging probe (LZ-550, FUJIFILM VisualSonics Inc.). The US/PA 
imaging system’s tunable Nd:YAG laser (20 Hz, 5-7 ns pulse length) was operated at two 
wavelengths. Brains were imaged at 760 nm at a laser fluence of 22 mJ/cm² and at 1064 
nm at a laser fluence of 24 mJ/cm². Imaging was performed at a US/PA frame rate of 5 
frames per second. Coronal 3D US/PA images at each wavelength were collected with a 
distance step size of 0.102 mm for a total of about 14 mm. 
5.2.6 US/PA image processing 
Coronal ultrasound and photoacoustic image sets were processed in MATLAB 
(Mathworks, Inc.). US/PA images were thresholded to reduce noise. US/PA image sets 
were also exported to generate 3D whole brain images using AMIRA (Thermo Scientific). 
For ex vivo images, transverse view and corner cut images of the treated (right) side of the 
brain, viewed from behind the cerebellum, were captured using AMIRA. In vivo images 
were also captured using AMIRA, with corner cut views of the treated (right) side of the 
brain shown.  
Image processing of 760 nm PFPnDs employed an algorithm previously described 
[30, 82]. Briefly, pixel-wise linear regression was performed on the ultrasound data sets 
captured in one 2D image plane of the brain over time. In the case of ultrasound-based 
analysis, pixels that had an increase in ultrasound signal amplitude over time corresponded 
to PFPnDs that were phase transitioning from liquid nanodroplets to gas microbubbles. 
Pixels with ultrasound signal amplitude increase rates above a certain threshold were 
identified, and a map of the above-threshold pixel rates was displayed over a co-registered 
ultrasound image, highlighting the location of PFPnDs within the image. All pixels 
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identified as vaporizing PFPnDs outside of the brain were rejected. From this method, US 
signal from PFPnDs within the brain can be localized.  
5.3 Results 
5.3.1 Characterization of perfluorocarbon nanodroplets 
Both PFCnD types, 760 nm PFPnDs and 1064 nm PFHnDs, were characterized by 
absorbance, size, and zeta potential (Figure 24). The absorbance of 760 nm PFPnDs was 
near 760 nm and the absorbance of 1064 nm PFPnDs was near 1064 nm (Figure 24A). 
These absorbance peaks correspond to absorption spectra of the optically absorbing dyes 
used in the synthesis of the PFCnDs, Epolight 9151 for 760 nm PFPnDs and IR-1048 for 
1064 nm PFHnDs (Figure 16A). In terms of size, 760 nm PFPnDs had a peak diameter of 
342 nm while 1064 nm PFHnDs had a peak diameter of 255 nm (Figure 24B). Zeta 
potential distributions of both PFCnDs were similar, with 760 nm PFPnDs having zeta 




Figure 24. Characterization of perfluorocarbon nanodroplets used for in vivo imaging.  
(A) Absorbance spectra for 760 nm perfluoropentane nanodroplets (PFPnDs) and for 1064 
nm perfluorohexane nanodroplets (PFHnDs). (B) Size distribution of 760 nm PFPnDs and 
1064 nm PFHnDs. (C) Zeta potential of 760 nm PFPnDs and 1064 nm PFHnDs.  
5.3.2 Ultrasound and photoacoustic imaging of extravasated IR-1048 dye 
For animals who only received optimized laser-activated PFHnD BBB opening, in 
vivo US/PA imaging was conducted (Figure 25). US/PA imaging at 1064 nm and 
conducted at t = 10 min showed little to no PA signal, denoted by the hot colormap overlaid 
on the US image, within the brain (Figure 25A). PA signal is visible near the skin and skull 
interface due to scattering of the laser light with the skin which can produce PA signal 
[133]. At t = 4 hours, PA signal within the brain is visible on the treated (right) side of the 
brain (Figure 25B) in addition to scattered signal from the skin. Further, ex vivo imaging 
of the fixed, excised brain also shows PA signal concentrated on the treated (right) side of 
the brain (Figure 25C). 
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Figure 25. Coronal 2D US/PA imaging at 1064 nm. (A) In vivo US/PA imaging at t = 10 
min. (B) In vivo US/PA imaging at t = 4 hours, showing localized 1064 nm PA signal 
within the dotted white circle on the treated (right) side of the brain. (C) Ex vivo imaging 
of the fixed, excised brain at 1064 nm, showing PA signal on the treated (right) side of the 
brain. 
Both in vivo and ex vivo US/PA images were reconstructed using 3D visualization 
software (AMIRA) to examine the extent of PA signal within the brain. In vivo 3D US/PA 
images agree with the 2D coronal images (Figure 25) in regards to the amount of dye 
delivered in the treated (right) side of the brain at the two different time points (Figure 26). 
US/PA imaging at t = 10 min shows minimal PA signal within the brain while at t = 4 hours 
an increase in PA signal volume is visible. Reconstructed ex vivo images also display the 
localized PA signal at 1064 nm on the treated (right) side of the brain which can be seen in 
the transverse and corner cut views of the ex vivo US/PA images (Figure 26). 
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Figure 26. Reconstructed in vivo 3D US/PA images at 1064 nm. Corner cut views of the 
treated (right) side of the brain are shown. (A) Reconstructed 3D US/PA image at t = 10 
min. (B) Reconstructed 3D US/PA image at t = 4 hours. 
 
Figure 27. Reconstructed ex vivo 3D US/PA images at 1064 nm. Image views include the 
transverse view and the corner cut view of the treated (right) side of the brain shown.  
Ex vivo imaging for animals who received optimized laser-activated PFHnD BBB 
opening were imaged at two wavelengths, 1064 nm and 760 nm, to examine the PA 
intensity of 1064 nm extravasated dye at 760 nm (Figure 28). PA signal intensity of 1064 
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nm dye needs to be considered when other PA contrast agents, such as those described in 
section 5.2.4, are to be delivered to the tissue. If the PA contribution of the 1064 nm dye 
delivered is too high, then it could prevent accurate localization of PA signal from the 
second contrast agent delivered without using methods such as PA spectroscopic analysis. 
Evaluating the signal of 1064 nm dye at 760 nm shows PA signal is present when the brain 
is imaged at 760 nm. However, in comparison to the average PA signal intensity at 1064 
nm and over the same region of interest, the PA signal intensity and spread is less at 760 
nm than at 1064 nm. 
 
Figure 28. Ex vivo imaging at two wavelengths, 760 nm and 1064 nm. (A) Ex vivo imaging 
at 1064 nm. (B) Ex vivo imaging at 760 nm. 
5.3.3 Ultrasound and photoacoustic imaging of delivered 760 nm perfluoropentane 
nanodroplets 
For animals where 760 nm PFPnDs were delivered via jugular injection after the 
BBB opening procedure was performed, in vivo US/PA imaging was only performed at t 
= 4 hours. PFPnDs are single phase change nanoparticles and therefore the dynamic US/PA 
imaging properties of a delivered set of PFPnDs can only be captured in one US/PA 
imaging session [75]. The results of the US/PA imaging and US signal processing of the 
 88 
laser-activated 760 nm PFPnDs shows localization of 760 nm PFPnDs within the brain 
(Figure 29), in the region where echogenic contrast and US/PA signal are present below 
the skin and skull. US/PA imaging at both 760 nm and 1064 nm shows scattered PA signal 
from the laser interaction with the skin, while US/PA imaging at both wavelengths also 
shows an image artifact caused by the metal stereotax ear bars [134]. 
Figure 29. In vivo 2D US/PA imaging showing the localization of PFPnD signal within 
the brain. (A) US/PA imaging at 760 nm showing localized PA signal, designated by the 
blue overlay, near the echogenic region inside the brain. (B) US/PA imaging at 1064 nm 
showing localized PA signal, designated by the red overlay, near the echogenic region 
inside the brain. (C) US imaging of the brain highlighting the echogenic region on the 
treated (right) side of the brain. (D) Plot of the US signal as frame number (i.e., time) 
increases over the echogenic region in (C) showing an increase in US signal amplitude 
over time. (E) US processed image using the algorithm mentioned in section 5.2.6, 
overlaying PFPnD pixels in yellow with the US image. (F) Merge of the US/PA signal at 
760 nm (blue), US/PA signal at 1064 nm (red), and US processed signal (yellow). 
Reconstructed 3D US/PA images of PA imaging at 760 nm, 1064 nm, and US 
signal processing were also generated (Figure 30). In the reconstructed images, PA signal 
at 760 nm and 1064 nm and the US signal processed for laser-activated 760 nm PFPnD 
behavior localizes the volume of 760 nm PFPnDs within the brain. In the reconstructed 3D 
US/PA images, scattered PA signal at 760 nm and 1064 nm is present, however, PA signal 
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at both wavelengths is also visible within the volume designated by the US processed 760 
nm PFPnD signal (highlighted in yellow).   
 
Figure 30. Reconstructed in vivo 3D US/PA images showing the localization of PFPnD 
signal within the brain. Corner cut views of the treated (right) side of the brain are shown. 
The zoomed-in image to the right of each whole brain image highlights the 3D 
reconstructed region of interest within the brain. (A) US image of the brain highlighting 
the echogenic region on the treated (right) side of the brain. (B) US processed image using 
the algorithm mentioned in section 5.2.6, overlaying PFPnD pixels in yellow with the US 
image. (C) US/PA imaging at 760 nm (blue overlay) and 1064 nm (red overlay) showing 
localized PA signal, near the echogenic region inside the brain. (D) Merge of the US/PA 
signal at 760 nm (blue), US/PA signal at 1064 nm (red), and US processed signal (yellow).  
Ex vivo images were also reconstructed at both PA imaging wavelengths (Figure 
31). Transverse and corner cut view images of the treated (right) side of the brain show the 
overlap between PA signal at 760 nm and 1064 nm.  
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Figure 31. Reconstructed ex vivo 3D US/PA images at 760 nm (blue), 1064 nm (red), and 
merge of PA signal captured at both wavelengths. Image views include the transverse view 
and the corner cut view of the treated (right) side of the brain shown. 
5.4 Discussion 
The imaging studies performed show how laser-activated PFHnD induced BBB 
opening enables delivery of US/PA contrast to the tissue. Further, US/PA contrast is 
delivered in sufficient quantities to allow for in vivo neuroimaging. In vivo imaging at 1064 
nm and t = 4 hours shows PA contrast from IR-1048 dye localized within the treated (right) 
side of the brain (Figure 25). In addition, the difference in PA imaging contrast from t = 10 
min to t = 4 hours on the treated side of the brain demonstrates how PA signal can change 
over time based on extravasation of PA contrast into the tissue. Ex vivo imaging at 1064 
nm confirms the delivery of 1064 nm dye to the tissue. US/PA signals are also 
reconstructed to 3D volumes to give a volumetric representation of the delivered PA signal 
(Figure 26, Figure 27). Further, when comparing ex vivo imaging at 1064 nm and 760 nm, 
it can be seen that PA signal intensity is less at 760 nm (Figure 28). This trend corresponds 
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to the IR-1048 dye having reduced optical absorption at 760 nm. As a result, if other PA 
absorbers are delivered to the tissue, such as 760 nm PFPnDs, PA signal at 760 nm should 
result primarily from the 760 nm PFPnDs. In addition, the PA signal intensity trend of IR-
1048 is expected to correspond with the absorbance spectrum of IR-1048 dye. Although 
these studies only evaluate IR-1048 dye at two wavelengths, future studies could include 
spectroscopic PA analysis. In vivo and ex vivo US/PA imaging could include spectral 
unmixing analysis to distinguish multiple photoabsorbers, endogenous and exogenous, 
found in the tissue [81].  
For delivery and imaging of 760 nm PFPnDs, PA signal at 760 nm and 1064 nm is 
evident; however, in these studies, PFPnDs are distinctly characterized by their US image 
contrast. Algorithms developed to track the US signal of the 760 nm PFPnDs over time 
allows for localization of PFPnD signal (Figure 29). Reconstructed in vivo 3D US/PA 
images also show the overlap in PA signal with US PFPnD signal (Figure 30), and 3D 
US/PA images reconstructed after ex vivo imaging show the volumetric footprint of PA 
signal delivered to the tissue at 1064 nm and 760 nm (Figure 31).  
Laser-activated PFHnD induced BBB opening and in vivo US/PA imaging 
combined is a useful tool for neuroimaging. US/PA imaging after laser-activated PFHnD 
induced BBB opening enables monitoring of BBB opening and extravasation. Although 
only two time points were used in the imaging sessions described above, BBB opening 
could be monitored over multiple time points, providing insight about the characteristic 
nature of laser-activated PFHnD induced BBB opening. Much like magnetic resonance 
(MR) guided focused ultrasound, the rate of opening can be examined using in vivo US/PA 
imaging as well as characteristics regarding BBB closing such as time of closing and rate 
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of closing [5]. Overall, US/PA in vivo imaging can be used to augment and improve the 
current methods used for laser-activated PFHnD induced BBB opening.  
Furthermore, in vivo US/PA imaging after delivery of additional contrast agents to 
the brain after laser-activated PFHnD induced BBB opening demonstrates the utility of 
US/PA imaging in neuroimaging. As laser-activated PFPnDs produce a single phase 
change event, they were allowed to circulate for four hours before US/PA imaging was 
conducted. As seen with in vivo imaging of the 760 nm PFPnDs, droplets were localized 
to the treated side of the brain, producing both US and PA contrast at a laser irradiation 
wavelength of 760 nm. This US and PA signal was also co-registered with the PA signal 
at 1064 nm, the peak wavelength of the optically triggered dye within the laser-activated 
PFHnD used for BBB opening. Although these imaging studies did not demonstrate 
distinctive spatial differences in signal for 760 nm PFPnDs and 1064 nm PFHnDs, they did 
demonstrate the ability to image the subpopulations of PA and US image contrast. To 
further resolve the location of droplets within the brain, histological staining can be 
performed. Specifically, laser-activated PFCnDs can be fluorescently tagged to determine 
their location within the tissue, providing insight regarding the ability of droplets to 
extravasate [82]. Thus, the use of multiplexed PFCnDs within neuroimaging has the ability 
to provide spatial information regarding US/PA image contrast over longer periods of time.  
In addition, there appears to be multiple benefits of laser-activated PFCnDs as a 
US/PA neuroimaging contrast agent. Although other PA contrast agents can be used, 
PFCnDs have advantages regarding their dual US/PA contrast. As seen in section 4.3, 760 
nm PFPnDs showed distinct US/PA contrast that produced a higher US and PA signal in 
comparison to CuS NPS. The 760 nm PFPnDs were also incubated at a lower concentration 
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than CuS NPs, which suggests better contrast can be obtained using 760 nm PFPnDs and 
at a lower dose. In addition, PFCnDs can be synthesized for biocompatibility and can 
contain already approved FDA components, expediting their translation to clinical 
applications in comparison to constructs made without FDA compliant materials. 
Targeting moieties are easily attachable to PFCnDs, making further steps toward molecular 
in vivo neuroimaging possible with laser-activated PFCnDs.  
Finally, as seen with the laser-activated PFHnDs used for BBB opening, a 
subpopulation of PFCnDs delivered for in vivo US/PA imaging can also be used for 
therapy. By relying on the phase change mechanisms and resulting cavitation-like behavior 
produced by laser-activated PFCnDs, a subpopulation of droplets could be used to destroy 
tumor cells or improve uptake of viral vectors for gene transfection [70, 71]. Additionally, 
extravasated PFCnDs can be used to carry therapeutics to the brain tissue for localized 
delivery, with delivery confirmation via US/PA imaging of therapeutic PFCnDs [70]. 
Therefore, PFCnDs present themselves not only as a promising contrast agent for US/PA 
neuroimaging but also as a multi-facetted therapeutic vehicle.    
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CHAPTER 6. CONCLUSIONS AND FUTURE WORK 
6.1 Laser-activated PFCnDs for BBB opening 
6.1.1 Conclusions 
In this work, blood brain barrier opening induced by laser-activated 
perfluorocarbon nanodroplets (PFCnDs) was evaluated on both the macroscopic and 
microscopic scales. Through evaluation of the technique via qualitative measurements of 
Evans Blue extravasation, histology, and ultrasound and photoacoustic (US/PA) imaging, 
it was demonstrated that laser-activated perfluorohexane nanodroplets (PFHnDs) can be 
used to open the blood brain barrier (BBB) and allow for various sized constructs, including 
antibodies, dyes, and red blood cells, to extravasate. Further, laser parameters, such as laser 
fluence and number of laser pulses used, involved in laser-activated PFHnD induced BBB 
opening were optimized for safety and efficacy. Using a quantitative analysis of 
fluorescence area produced from immunoglobulin (IgG) extravasation and volumetric PA 
signal from PA dye extravasation, trends in BBB opening were determined. Overall, laser-
activated PFCnDs were shown to successfully open the BBB, and opening can be tuned 
through adjustment of laser parameters used.  
6.1.2 Improving laser-activated PFCnD BBB opening  
Although these studies show the effectiveness of laser-activated PFHnD induced 
BBB opening, there is also opportunity to further optimize PFCnDs as a mechanical agent. 
In particular, laser-activated PFCnD parameters should also be explored. Parameters such 
as PFCnD size, concentration, perfluorocarbon core, and encapsulated optical trigger are 
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worth examining to determine the optimal setup for laser-activated PFCnD induced BBB 
opening.  
Furthermore, laser-activated PFCnD induced BBB opening should be compared to 
acoustically activated PFCnD induced BBB opening with focused ultrasound. Direct 
evaluation of the two different energy sources for PFCnD phase change allows for a clearer 
understanding of the advantages and disadvantages of focused ultrasound (FUS) and laser 
light in the process of BBB opening using PFCnDs. In particular, laser-activated PFCnD 
induced BBB opening will experience limitations in comparison to FUS with respect to 
depth penetration. Laser depth penetration is limited due to the scattering and absorption 
of light in tissue [57]. The laser energy used in these experiments obeys Beer’s Law, which 
states that the energy deposited decays exponentially with distance. Using wavelengths at 
the far end of the near-infrared spectrum, such as 1064 nm, can increase this depth 
penetration to ~1 cm [57]. However, if a deeper opening depth is desired, laser-activated 
PFCnDs will fall short in efficacy. In the case of PFCnD induced BBB opening at greater 
depths, FUS induced BBB opening has been demonstrated [96]. Therefore, a main 
advantage of BBB opening by FUS vaporized PFCnDs is its ability to create a focal 
opening in the BBB at depths greater than that of laser-activated droplets. However, this 
FUS PFCnD activation often requires high ultrasonic pressures, which can cause damage 
to the tissue [73, 96]. Thus, FUS PFCnD induced BBB opening also has limitations.  
To overcome these challenges, it is hypothesized that a FUS field simultaneously 
triggered with a laser pulse will enable PFCnD activation and allow opening to occur 
locally in the FUS field. PFCnDs circulating will be sensitive to both the FUS field and 
laser energy, enabling vaporization at lower laser energies and at increased depths while 
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maintaining lower and safer ultrasound pressures. Combined phase change of PFCnDs with 
laser light and FUS energy has been demonstrated previously for imaging purposes and is 
described as sono-photoacoustic activation [135, 136]. In sono-photoacoustic activation, 
laser irradiation is synchronized with the peak rarefractional phase of the acoustic pulse to 
enable phase change at significantly lower thresholds [135, 136]. As result, this dual energy 
activation can be translated to BBB opening, allowing for a reduction in the intensity of 
energies used to phase change PFCnDs and initiate BBB opening. 
6.1.3 Examining physiological response caused by BBB opening 
As laser-activated PFCnDs are an exogeneous agent, the immune response of the 
body to PFCnDs should be examined. Although damage to the tissue can be assessed using 
histological stains such as hematoxylin and eosin, further investigation into changes in 
morphology and behavior of different cells within the brain is warranted. For example, 
immunohistochemical staining of ionized calcium-binding adapter molecule 1 (IBA1) can 
provide information regarding microglial activation. Because microglia play a key role in 
the immune response within the brain, changes to their behavior after BBB opening are 
important to examine [126, 132]. Preliminary studies of IBA1 staining show that for 
unoptimized laser-activated PFHnD induced BBB opening, there appears to be a difference 
in microglial activation on the treated side of the brain in comparison to a control where no 
laser-activated PFHnD induced BBB opening occurred (t = 4 hours post BBB opening, 
Figure 32).  
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Figure 32. Immunohistochemical staining for IBA1 (red), a microglial marker, and DAPI 
(blue). Control pictomicrographs (A-B), where no BBB opening occurred, show no 
microglial activation on either the left (untreated) or right (treated) side of the brain. 
However, when laser-activated BBB opening occurs, microglial activation is visible on the 
right (treated) side of the brain (C-D).   
Furthermore, the effects of laser-activated PFCnD induced BBB opening should be 
studied for time points of longer than t = 4 hours, the time point of euthanasia for the in 
vivo studies described. After performing laser-activated PFCnD induced BBB opening, 
animals should be evaluated over time points of days or weeks. These longer time points 
will not only allow for further evaluation of microglia but also other cells within the brain 
such as astrocytes or neurons. As seen with studies with microbubble assisted FUS BBB 
opening, an acute inflammatory response occurs at certain microbubble doses and acoustic 
pressures used [137]. Therefore, it is likely laser-activated PFCnD induced BBB opening 
will have a similar immune response.   
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Not only is immune response important for understanding for laser-activated 
PFCnD induced BBB opening, but the characteristic nature of the BBB opening is also 
important to examine. Specifically, the rates of BBB opening and closing are important 
parameters to determine the treatment window available using laser-activated PFHnDs. For 
microbubble assisted FUS, the time window ranges from 4 to 24 hours [5, 102]. Although 
the laser-activated PFCnD induced BBB opening is expected to follow this trend, it is 
important to experimentally validate this behavior.  
6.1.4 Laser-activated PFCnDs to open other biological barriers 
In addition to the blood brain barrier, it seems promising to utilize laser-activated 
PFCnDs in opening other biological barriers. Specifically, laser-activated PFCnDs can be 
utilized to open the blood spinal cord barrier (BSCB). This other neurological barrier is a 
major challenge for many diseases and disorders of the CNS. One example includes 
effective delivery of gene therapy to the spinal cord, which has been a challenge for 
clinicians and researchers [4]. Gene therapy in the spinal cord has long been a challenge 
due not only to the BSCB but also to the spinal column. Traditional methods used to treat 
spinal cord injury or ALS involve removal of the spinal bone and direct injections [4]. 
Laser-activated PFCnDs induced BSCB opening has the potential to noninvasively and 
locally deliver viral vectors to the spinal cord for gene therapy. In particular, AAV9 crosses 
the BBB and BSCB, however, microbubble assisted FUS BSCB opening has shown to 
enable localized and more concentrated delivery of this virus [4]. Thus, laser-activated 
PFCnDs can be implemented similarly, with laser light only or combined with FUS, to 
permeabilize the BSCB and allow for therapeutic treatments.  
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Laser-activated PFCnDs can also be implemented to create pores in cell membranes 
similarly to sonoporation, a method that uses microbubbles and FUS to create openings in 
cell membranes [138]. Laser-activated PFCnDs have been shown to increase uptake of 
intracellularly specific fluorescent dyes, highlighting the potential for laser-activated 
PFCnDs in a wide range of treatments including enhanced drug delivery for tumor 
treatment [138, 139].  
6.2 Laser-activated PFCnDs for US/PA neuroimaging 
6.2.1 Conclusions 
Laser-activated PFCnDs are shown in this work as a useful US/PA imaging contrast 
agent for neuroimaging. Specifically, laser-activated PFPnDs were used to produce 
dynamic imaging contrast within the brain. Laser-activated PFPnDs were evaluated for 
their dynamic, enhanced dual US/PA contrast, producing sufficient US/PA signal up to 24 
hours in in vitro studies. In addition, the in vivo US signal produced by laser-activated 
PFPnDs was tracked and co-registered with the PA signal produced by the droplets to 
enable localization of PFPnDs within the brain. Furthermore, laser-activated PFHnDs used 
for BBB opening were able to deliver PA sensitive dye in sufficient amounts to allow for 
imaging of extravasation over time. As a result, laser-activated PFCnDs are presented as a 
promising tool to enhance US/PA neuroimaging.  
6.2.2 Improving US/PA neuroimaging methods 
Although in vivo US/PA imaging methods were able to detect PA contrast within 
the brain, there are a few areas in which US/PA imaging can be improved. Specifically, 
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US/PA imaging systems can be improved. The current imaging setup relies on a US/PA 
imaging system that limits user modification of the imaging sequences and parameters. 
However, other imaging systems such as a tunable laser source and user-programmable 
ultrasound imaging setup would allow for more versatile imaging techniques [140]. In 
addition, hardware for signal amplification could be added to enable improved receive of 
US and PA signals as they travel across the skull to the US receiver. Not only can hardware 
changes improve the acquisition capabilities for US/PA neuroimaging, but improved signal 
processing techniques are also possible. In particular, methods can be developed to reduce 
artifacts from the scattering at the skin and metal ear bars, allowing for improved 
visualization of PA signal from within the brain.  
Additionally, in vivo US/PA imaging can be improved through spectroscopic 
photoacoustic analysis. In addition to PA signal produced via exogenous contrast, 
endogenous absorbers, such as oxygenated and deoxygenated hemoglobin, could be 
considered. Because PA contrast agents have unique optical signatures related to their 
absorption spectra, they can be separated from any endogenous PA contrast [57]. Through 
spectroscopic unmixing, separate imaging contrast provided by subpopulations of laser-
activated PFCnDs could not only be identified via their dynamic US and PA imaging 
behavior but also by their optical absorption spectra.  
6.2.3 Applications of US/PA neuroimaging 
Through the combination of laser-activated PFCnDs induced BBB opening and 
US/PA imaging of delivered PA contrast agents, the ability to quantitatively and 
longitudinally measure PA signal in the brain is possible. This capability enables real time 
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monitoring of brain function and how this may change with a disease state. One specific 
application of this particular method is for use in Alzheimer’s disease. By functionalizing, 
via antibody conjugation or other targeting moiety, the PA contrast agent, whether that be 
optimized PFCnDs, CuS NPs, or another PA sensitive contrast agent, can target plaques or 
tau proteins within the brain allowing the state of Alzheimer’s disease to be evaluated in 
vivo [141, 142]. As the disease progresses, PA signal can be monitored longitudinally to 
see how the distribution of the disease state changes within the tissue [142, 143]. This data 
is of particular interest as current imaging techniques are unable to capture this information 
and provide insight into the disease progression on a molecular level in a way US/PA 
imaging with PA contrast agents can [115, 144]. Not only can PA contrast agents be used 
to monitor diseased tissue changes, but it also can be used to provide an improved 
understanding of the clearance system of the brain [143]. Thus, in the area of basic science, 
PA imaging has the potential to provide more insight into how the normal brain functions. 
Overall, this technique could enable an improved understanding of neurological function 
in both normal and diseased brain states.  
6.3 Summary of conclusions and future directions 
These studies demonstrate the usefulness of laser-activated PFCnDs in neurological 
applications. Specifically, laser-activated PFHnDs have been shown to open the BBB, 
allowing for extravasation of various sized constructs. The laser parameters for laser-
activated PFHnD induced BBB opening have been optimized to enable safe and efficient 
opening. Furthermore, laser-activated PFCnDs have been evaluated as a US/PA imaging 
contrast agent for in vivo neuroimaging. Thus, these studies establish laser-activated 
PFCnDs in neurological imaging and therapy, demonstrating laser-activated PFCnDs as a 
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versatile tool with the potential to impact treatment and monitoring of neurological 
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